

A Generalized Logrank-type Test for Comparison of Treatment Regimes in Sequential Multiple Assignment Randomized Trials

Anastasios A. Tsiatis* and Marie Davidian**

Department of Statistics, North Carolina State University, Raleigh, NC, USA.

**email:* tsiatis@ncsu.edu

***email:* davidian@ncsu.edu

SUMMARY: The sequential multiple assignment randomized trial (SMART) is the ideal study design for the evaluation of multistage treatment regimes, which comprise sequential decision rules that recommend treatments for a patient at each of a series of decision points based on their evolving characteristics. A common goal is to compare the set of so-called embedded regimes represented in the design on the basis of a primary outcome of interest. In the study of chronic diseases and disorders, this outcome is often a time to an event, and a goal is to compare the distributions of the time-to-event outcome associated with each regime in the set. We present a general statistical framework in which we develop a logrank-type test for comparison of the survival distributions associated with regimes within a specified set based on the data from a SMART with an arbitrary number of stages that allows incorporation of covariate information to enhance efficiency and can also be used with data from an observational study. The framework provides clarification of the assumptions required to yield a principled test procedure, and the proposed test subsumes or offers an improved alternative to existing methods. We demonstrate performance of the methods in a suite of simulation studies. The methods are applied to a SMART in patients with acute promyelocytic leukemia.

KEY WORDS: Augmented inverse probability weighting; Dynamic treatment regime; Estimating function; Potential outcomes

1. Introduction

Clinicians caring for patients with chronic diseases and disorders typically make sequential treatment decisions at key points in a patient’s disease or disorder progression. For example, treatment of cancer patients involves a series of decisions at the times of diagnosis, remission or failure to achieve remission, recurrence, and so on. Clinicians make these decisions based on accrued information on the patient, including how the patient responded to previous treatments, with the goal of optimizing a long-term health outcome.

A treatment regime is a sequence of decision rules, each rule corresponding to a key decision point and mapping accrued information on the patient to a recommended treatment option chosen from among those feasible for the patient. Thus, treatment regimes formalize the clinical decision-making process and provide a strategy for treating an individual patient. Sequential multiple assignment randomized trials (SMARTs) (Lavori and Dawson, 2004; Murphy, 2005), which involve multiple stages of randomization of participants, where each stage corresponds to a key decision point, are ideally suited to the study of treatment regimes, and SMARTs have been conducted in a range of disease and disorder areas (Almirall et al., 2014; Kidwell, 2014; Lorenzoni et al., 2023; Bigirimurame et al., 2022). In a SMART, the treatment options to which a subject can be assigned at any stage can depend on the subject’s past history, including previous treatments and responses to them, and the design of the SMART defines a set of regimes, known as the SMART’s embedded regimes. Primary or secondary analyses in a SMART often focus on comparison of all or a subset of the embedded regimes on the basis of a health outcome of interest.

There is an extensive literature on methods for inference on treatment regimes, including well-established methods for inference on a specified set of given regimes, such as the embedded regimes in a SMART (Nahum-Shani and Almirall, 2019; Tsiatis et al., 2020). The majority assume a continuous or discrete outcome that is observed for all subjects, and

interest focuses on comparison of the mean outcomes that would be achieved if the entire patient population were to receive treatments according to the rules in each regime in the set. In many chronic diseases and disorders, the relevant outcome is a time to an event, e.g., in cancer, disease-free or overall survival time, and, as in conventional (single-stage) clinical trials, interest is instead in comparison of the event-time (survival) distributions if the patient population were to receive treatments according to the rules in each regime. A further complication that arises in the context of a SMART or other study giving rise to data to be used for this purpose is that the outcome may be censored for some subjects.

This situation is exemplified by North American Leukemia Intergroup Study C9710, coordinated by the Cancer and Leukemia Group B, now part of the Alliance for Clinical Trials in Oncology, in patients with acute promyelocytic leukemia (APL) (Powell et al., 2010). The primary outcome was a composite of time to failure to achieve complete remission (CR), relapse after achieving CR, or death, whichever came first, referred to as event-free survival (EFS) time. Study C9710 was a SMART with two stages, as depicted in Figure 1: All subjects were to receive the same induction chemotherapy and were then randomized at stage 1 to one of two consolidation therapies, two courses of all-trans-retinoic acid (ATRA) or two courses of ATRA combined with arsenic trioxide; thus, the first decision point corresponds to choice of consolidation therapy. Those not experiencing the event by completion of consolidation therapy were to be randomized at the second stage to receive maintenance therapy of ATRA alone or ATRA plus oral methotrexate (Mtx) and mercaptopurine (MP); thus, the second decision point corresponds to choice of maintenance therapy for patients who complete consolidation. Study C9710 involves four embedded regimes; e.g., one of these administers ATRA consolidation therapy at the first decision and, if the patient does not experience an event by the end of consolidation, administers ATRA+Mtx+MP maintenance therapy at the second decision. For some subjects, EFS time was not observed because it did not

occur during the study period, i.e., was administratively censored, or was censored due to loss to follow up. Of necessity, subjects for whom the outcome occurred or was censored during consolidation were not re-randomized. Although the original goal was not to compare the embedded regimes, the trial presents the opportunity for further insight on how best to sequence these therapies in the treatment of APL patients.

[Figure 1 about here.]

A number of methods for comparing regimes in a specified set of regimes on the basis of a time-to-event outcome have been proposed. Some authors focus on comparing survival probabilities only at a single time point (Lunceford, Davidian, and Tsiatis, 2002), while others propose logrank-type tests for comparing survival distributions (Guo and Tsiatis, 2005; Feng and Wahed, 2008; Li and Murphy, 2011; Kidwell and Wahed, 2013; Li et al., 2014). Early works limit comparisons to two regimes that assign different stage 1 treatments. Kidwell and Wahed (2013) and Li et al. (2014) propose tests for comparing ≥ 2 regimes, including “shared path” regimes for which the stage 1 treatment is the same. The former authors restrict to comparison of the embedded regimes in a particular two-stage SMART with four embedded regimes. The latter consider comparison of regimes involving, in principle, any number of decision points based on data from a SMART or observational study, although the approach is demonstrated only in the case of the same two-stage four-regime setting as Kidwell and Wahed (2013). Both methods have potential shortcomings, discussed in the sequel.

In this article, we propose a general framework from which to derive a logrank-type test for comparing an arbitrary set of regimes for any number of decision points; e.g., in a SMART, all or a subset of the embedded regimes. In addition to providing a test statistic for the null hypothesis of no difference in survival distributions for a set of regimes, unlike existing methods, the framework also yields a covariate-adjusted statistic that uses baseline and intermediate covariate information to increase efficiency, resulting in more powerful

tests. Although we focus on SMARTs, the methodology also can be used with observational data and includes the approach of Li et al. (2014). In Section 2, we present the framework and the proposed test procedures, and we contrast our approach to existing methods. We present results of a suite of simulation studies demonstrating performance of the methods in Section 3, and we apply the methods to Study C9710 in Section 4.

2. Statistical framework and methodology

2.1 Problem formulation

We first characterize a treatment regime when the outcome is a time to an event. Consider K decision points, where at Decision k , $k = 1, \dots, K$, \mathcal{A}_k is the finite set of all treatment options. Following Tsiatis et al. (2020, Section 8.3.1), let \mathbf{x}_1 be the information available on an individual at Decision 1 at time $\tau_1 = 0$ (baseline), such as demographics, medical history variables, clinical and physiologic measures, and so on; and let $a_1 \in \mathcal{A}_1$ be the treatment option given at Decision 1. For $k = 2, \dots, K$, if an individual does not experience the event between Decisions $k - 1$ and k , let τ_k be the time Decision k is reached; \mathbf{x}_k be additional information obtained between Decisions $k - 1$ and k ; e.g., updated clinical and physiologic measures, timing and severity of adverse reactions to and response to prior treatments, etc.; and $a_k \in \mathcal{A}_k$ be the option given at Decision k . Then, at Decision 1, the history of information available on an individual is $\mathbf{h}_1 = (\tau_1, \mathbf{x}_1)$, and, defining $\bar{a}_k = (a_1, \dots, a_k)$, $k = 1, \dots, K$, and $\bar{\tau}_k$ and $\bar{\mathbf{x}}_k$ similarly, the accrued history of information available at Decision k for an individual who reaches Decision k without having experienced the event is $\mathbf{h}_k = (\bar{\tau}_k, \bar{\mathbf{x}}_k, \bar{a}_{k-1})$, $k = 2, \dots, K$. For an individual who experiences the event at time t between Decisions $k - 1$ and k , the history for $j = k, \dots, K$ is $\mathbf{h}_j = (\bar{\tau}_k, \bar{\mathbf{x}}_k, \bar{a}_{k-1}, t)$. A treatment regime d is a set of decision rules $d = \{d_1(\mathbf{h}_1), \dots, d_K(\mathbf{h}_K)\} = (d_1, \dots, d_K)$, where, for an individual for whom \mathbf{h}_k indicates the event has not yet occurred, the k th rule $d_k(\mathbf{h}_k)$

returns a treatment option in the subset $\Psi_k(\mathbf{h}_k) \subseteq \mathcal{A}_k$ that is feasible for an individual with history \mathbf{h}_k . If \mathbf{h}_k indicates that the event has occurred, $d_k(\mathbf{h}_k)$ makes no selection, and $\Psi_k(\mathbf{h}_k)$ is the empty set. As in Tsiatis et al. (2020, Section 6.2.2), at Decision k there may be ℓ_k subsets of \mathcal{A}_k that are feasible sets for different histories. If $s_k(\mathbf{h}_k) = 1, \dots, \ell_k$ indicates the relevant feasible subset for \mathbf{h}_k , $d_k(\mathbf{h}_k)$ is typically a composite of subset-specific rules; write $d_k(\mathbf{h}_k) = \sum_{l=1}^{\ell_k} I\{s_k(\mathbf{h}_k) = l\} d_{k,l}(\mathbf{h}_k)$, where $d_{k,l}(\mathbf{h}_k)$ selects options from the l th subset.

In a SMART, the feasible sets and regimes that can be studied are dictated by the design. For example, consider the SMART in Figure 2, with $K = 2$. Here, $\Psi_1(\mathbf{h}_1) = \mathcal{A}_1 = \{0, 1\}$ for any \mathbf{h}_1 , and regimes that can be studied based on this trial have rules $d_1(\mathbf{h}_1)$ that return one of the treatments in \mathcal{A}_1 . At Decision 2, $\Psi_2(\mathbf{h}_2)$ is the empty set for subjects who experience the event prior to Decision 2; otherwise, $\Psi_2(\mathbf{h}_2)$ is a subset of $\mathcal{A}_2 = \{2, 3, 4, 5\}$ determined by the stage 1 treatment and response status contained in histories \mathbf{h}_2 for which the event has not yet taken place, so that regimes that can be studied have rules $d_2(\mathbf{h}_2)$ that are a composite of subset-specific rules. E.g., if \mathbf{h}_2 indicates that $a_1 = 1$ and the individual is a responder, $\Psi_2(\mathbf{h}_2) = \{2, 5\}$, and a subset-specific rule selects Decision 2 treatment from this subset. The SMART in Figure 2 has eight embedded regimes satisfying these conditions.

[Figure 2 about here.]

We formalize the null hypothesis of interest in terms of the potential outcomes framework in Tsiatis et al. (2020, Section 8.3.2), who define for any sequence of treatment options $\bar{a}_K \in \mathcal{A}_1 \times \dots \times \mathcal{A}_K$ that could hypothetically be given to an individual, the potential number of decision points that would be reached and potential times at which they would be reached, potential covariate information that would arise, and the associated potential event time. As in (8.50) of Tsiatis et al. (2020), denote by \mathcal{W}^* the collection of these potential variables for all possible sequences. For any regime d and associated feasible sets, it is possible to define in terms of \mathcal{W}^* $T^*(d)$, the potential time to the event if a randomly chosen individual in the

population were to receive treatments by following the rules in d . Denote the hazard rate of experiencing the event at time u for an individual following the rules in d by $\lambda(u, d) = \lim_{du \rightarrow 0} du^{-1} P\{u \leq T^*(d) < u + du | T^*(d) \geq u\}$, $u \geq 0$. Then, given a set $\mathcal{D} = \{d^1, \dots, d^D\}$ of D regimes of interest, e.g., the embedded regimes in a SMART or a subset thereof, we are interested in testing the null hypothesis

$$H_0: \lambda(u, d^1) = \dots = \lambda(u, d^D), \quad u \geq 0, \quad (1)$$

versus the alternative hypothesis that at least one hazard rate differs from the rest.

Analogous to the formulation of the standard logrank test in a conventional (single-stage) multi-arm clinical trial, to motivate our proposed test of H_0 in (1), for the regimes d^j , $j = 1, \dots, D$, of interest, assume a proportional hazards relationship; namely

$$\lambda(u, d^j) = \lambda_0(u) \exp(\beta_j), \quad j = 1, \dots, D - 1. \quad (2)$$

Under (2), the baseline hazard $\lambda_0(u)$ is $\lambda(u, d^D)$, and (1) corresponds to $H_0: \beta_1 = \dots = \beta_{D-1} = 0$. As with the standard logrank test, we do not necessarily believe that (2) holds. In fact, (2) generally cannot hold; e.g., intuitively, the hazards for two “shared path” regimes cannot be proportional under departures from H_0 . Rather, (2) is solely a convenient mechanism by which to motivate a test of (1).

Toward that goal, we consider the possibly misspecified model (2) and develop a test statistic in the spirit of generalized score tests (Boos, 1992). For any regime d , let $N^*(u, d) = I\{T^*(d) \leq u\}$ and $Y^*(u, d) = I\{T^*(d) \geq u\}$ be the event-time counting process and at-risk process, respectively, associated with $T^*(d)$. Assuming (2) holds and letting $\Lambda_0(u) = \int_0^u \lambda_0(s) ds$ and $\Lambda(u, d) = \int_0^u \lambda(s, d) ds$ denote the cumulative hazard functions associated with $\lambda_0(u)$ and $\lambda(u, d)$, respectively, $E\{dN^*(u, d) - d\Lambda(u, d)Y^*(u, d)\} = 0$. Then for the set \mathcal{D} of regimes of interest,

$$E\{dN^*(u, d^D) - d\Lambda_0(u)Y^*(u, d^D)\} = 0,$$

$$E\{dN^*(u, d^j) - d\Lambda_0(u) \exp(\beta_j) Y^*(u, d^j)\} = 0, \quad j = 1, \dots, D - 1,$$

which defines a dynamic regime marginal structural model (Orellana, Rotnitzky, and Robins,

2010). If we were able to observe $T^*(d^j)$ for all $j = 1, \dots, D$, and if (2) were correct, then, analogous to Yang, Tsiatis, and Blazing (2018), for each regime $j = 1, \dots, D$, we would be led to a set of estimating functions for $\Lambda_0(u)$, $u \geq 0$, and $\beta_1, \dots, \beta_{D-1}$. That associated with $\Lambda_0(u)$, $u \geq 0$, is the infinite-dimensional expression

$$dN^*(u, d^j) - d\Lambda_0(u) \exp \left\{ \sum_{j'=1}^{D-1} \beta_{j'} I(j' = j) \right\} Y^*(u, d^j), \quad u \geq 0;$$

that associated with $\beta_{j'}$, $j' = 1, \dots, D-1$, is

$$\int_0^\infty I(j' = j) \left[dN^*(u, d^j) - d\Lambda_0(u) \exp \left\{ \sum_{j'=1}^{D-1} \beta_{j'} I(j' = j) \right\} Y^*(u, d^j) \right].$$

Note that this expression is equal to zero except when $j' = j$. Following Orellana et al. (2010) and Yang et al. (2018), we can combine these estimating functions across the D regimes in \mathcal{D} via a weighted sum, yielding the estimating functions

$$\sum_{j=1}^D w(u, d^j) \left[dN^*(u, d^j) - d\Lambda_0(u) \exp \left\{ \sum_{j'=1}^{D-1} \beta_{j'} I(j' = j) \right\} Y^*(u, d^j) \right], \quad u \geq 0, \quad (3)$$

$$\int_0^\infty w(u, d^j) \{ dN^*(u, d^j) - d\Lambda_0(u) \exp(\beta_j) Y^*(u, d^j) \}, \quad j = 1, \dots, D-1, \quad (4)$$

where, for any regime d , $w(u, d)$ is a possibly time-dependent weight function discussed later.

Now, under H_0 : $\beta_1 = \dots = \beta_{D-1} = 0$, if it were possible to observe $T^*(d^j)$, $j = 1, \dots, D$, for each of the n participants in a SMART, indexing individuals by $i = 1, \dots, n$, from (3), for any $u \geq 0$, the “score equation” associated with the “nuisance parameter” $\Lambda_0(u)$ is

$$\sum_{i=1}^n \sum_{j=1}^D w(u, d^j) \{ dN_i^*(u, d^j) - d\Lambda_0(u) Y_i^*(u, d^j) \} = 0, \quad (5)$$

yielding $d\hat{\Lambda}_0(u) = \{ \sum_{i=1}^n \sum_{j=1}^D w(u, d^j) dN_i^*(u, d^j) \} / \{ \sum_{i=1}^n \sum_{j=1}^D w(u, d^j) Y_i^*(u, d^j) \}$. From (4), the “score equation” associated with β_j is $\sum_{i=1}^n \int_0^\infty w(u, d^j) \{ dN_i^*(u, d^j) - d\Lambda_0(u) Y_i^*(u, d^j) \}$; substituting $d\hat{\Lambda}_0(u)$ yields the $(D-1)$ -dimensional “score vector” \mathfrak{T}^* associated with $\beta_1, \dots, \beta_{D-1}$, with j th element

$$\sum_{i=1}^n \int_0^\infty w(u, d^j) \{ dN_i^*(u, d^j) - d\hat{\Lambda}_0(u) Y_i^*(u, d^j) \}. \quad (6)$$

Thus, a test statistic for H_0 could be constructed as a quadratic form in \mathfrak{T}^* .

Of course, for a given set of regimes \mathcal{D} , we cannot observe $T^*(d^j)$, $j = 1, \dots, D$, for each

subject in a SMART (or observational study). Thus, to exploit these developments, we must relate these potential outcomes and (5)-(6) to the data actually available, discussed next.

2.2 Data and test procedure

As in Study C9710, the event time for some subjects may be censored. Thus, following Tsiatis et al. (2020, Section 8.3.2), the observed data on a participant in a K -stage SMART (or observational study) can be represented as

$$\mathcal{O} = \{\kappa, \mathcal{T}_1, \mathbf{X}_1, A_1, \mathcal{T}_2, \mathbf{X}_2, A_2, \dots, \mathcal{T}_\kappa, \mathbf{X}_\kappa, A_\kappa, U, \Delta\}, \quad (7)$$

where κ is the observed number of decision points reached by the subject before experiencing the event or censoring, $1 \leq \kappa \leq K$; $A_1 \in \mathcal{A}_1$ is the treatment option received at time $\mathcal{T}_1 = 0$ (baseline); \mathcal{T}_k , $k = 2, \dots, \kappa$, are the observed times at which the subject reached Decisions $2, \dots, \kappa$, at which they received treatment options $A_k \in \mathcal{A}_k$, $k = 2, \dots, \kappa$; and \mathbf{X}_1 is baseline covariate information and \mathbf{X}_k , $k = 2, \dots, \kappa$, is the additional covariate information collected on the individual between Decisions $k-1$ and k . In (7), U is the observed time to the event or censoring, whichever comes first, and $\Delta = 1$ or 0 as U is the event or censoring time. Finally, writing $\bar{A}_k = (A_1, \dots, A_k)$, $k = 1, \dots, \kappa$, and $\bar{\mathbf{X}}_k$ and $\bar{\mathcal{T}}_k$ similarly, the observed history up to Decision k is $\mathbf{H}_1 = (\mathcal{T}_1, \mathbf{X}_1)$, $k = 1$, and, for $k = 2, \dots, K$, $\mathbf{H}_k = (\bar{\mathcal{T}}_k, \bar{\mathbf{X}}_k, \bar{A}_{k-1})$, $\kappa \geq k$, and $\mathbf{H}_k = (\bar{\mathcal{T}}_\kappa, \bar{\mathbf{X}}_\kappa, \bar{A}_\kappa, U, \Delta)$, $\kappa < k$. As in (8.62) of Tsiatis et al. (2020, Section 8.3.2), the history available up to time $u \geq 0$ can be expressed as

$$H(u) = \{(\mathcal{T}_1, \mathbf{X}_1, A_1), I(\kappa \geq 2, \mathcal{T}_2 \leq u), I(\kappa \geq 2, \mathcal{T}_2 \leq u)(\mathcal{T}_2, \mathbf{X}_2, A_2), \dots, I(\kappa \geq k, \mathcal{T}_k \leq u), \\ I(\kappa \geq k, \mathcal{T}_k \leq u)(\mathcal{T}_k, \mathbf{X}_k, A_k), k = 3, \dots, K, I(U < u), (U, \Delta)I(U < u)\}.$$

It is possible to obtain analogs to (5) and (6) in terms of the observed data (7) under standard identifiability assumptions, which are discussed in detail in Tsiatis et al. (2020, Section 8.3.2). The consistency assumption in these authors' (8.66) states that the observed data are equal to their potential analogs under the treatments actually received. The se-

quential randomization assumption (SRA) states that $\mathcal{W}^* \perp\!\!\!\perp A_k | (\mathbf{H}_k, \kappa) \geq k$, $k = 1, \dots, K$, where “ $\perp\!\!\!\perp$ ” denotes statistical independence, which is guaranteed by randomization in a SMART but must be made based on domain considerations in an observational study. We assume that censoring is noninformative in the sense that the cause-specific hazard for censoring satisfies $\lambda_c\{u|H(u), \mathcal{W}^*\} = \lim_{du \rightarrow 0} du^{-1} P\{u \leq U < u + du, \Delta = 0 | U \geq u, H(u), \mathcal{W}^*\} = \lim_{du \rightarrow 0} du^{-1} P\{u \leq U < u + du, \Delta = 0 | U \geq u, H(u)\} = \lambda_c\{u|H(u)\}$, say, so that censoring depends only on information observed through time u . The positivity assumption states roughly that $\omega_k(\mathbf{h}_k, a_k) = P(A_k = a_k | \mathbf{H}_k = \mathbf{h}_k, \kappa \geq k) > 0$ for all \mathbf{h}_k such that $P(\mathbf{H}_k = \mathbf{h}_k, \kappa \geq k) > 0$ and $a_k \in \Psi_k(\mathbf{h}_k)$, $k = 1, \dots, K$, which is true by design in a SMART; see Tsiatis et al. (2020, Section 8.3.2) for a precise formulation.

Under these assumptions, analogs to (5) and (6) in terms of the observed data are based on inverse probability weighting. For regime d and $u \geq 0$, define

$$C(u, d) = \prod_{k=1}^{\kappa} [I\{\mathcal{T}_k > u\} + I\{\mathcal{T}_k \leq u\} I\{A_k = d_k(\mathbf{H}_k)\}], \quad u \geq 0, \quad (8)$$

the indicator of whether or not the treatments received by an individual through u are consistent with having followed the rules in d through u . Similarly, define

$$\pi(u, d) = \prod_{k=1}^{\kappa} [I\{\mathcal{T}_k > u\} + I\{\mathcal{T}_k \leq u\} \omega_k\{\mathbf{H}_k, d_k(\mathbf{H}_k)\}], \quad u \geq 0. \quad (9)$$

Dependence of $C(u, d)$ and $\pi(u, d)$ on $H(u)$ is suppressed for brevity. As an example, consider the SMART in Figure 2, with $K = 2$ and the embedded regime $d = (d_1, d_2)$ that gives Trt a at Decision 1, and, if the event does not occur before Decision 2, gives Trt b if an individual is a responder and Trt c if not. Because in this SMART $\Psi_1(\mathbf{h}_1) = \{0, 1\}$ for all \mathbf{h}_1 , $I\{A_1 = d_1(\mathbf{H}_1)\} = I(A_1 = a)$ and $\omega_1\{\mathbf{H}_1, d_1(\mathbf{H}_1)\} = P(A_1 = a)$, the probability of being randomized to Trt a at stage 1. Thus, if $\kappa = 1$, as $\mathcal{T}_1 = 0$, $C(u, d) = I(A_1 = a)$ and $\pi(u, d) = P(A_1 = a)$ for all $u \geq 0$. If $\kappa = 2$, letting $R_2 = 1$ (0) if an individual responds (does not respond) to stage 1 treatment, where R_2 is a function of \mathbf{X}_2 and thus \mathbf{H}_2 , $d_2(\mathbf{h}_2)$ is a composite of two subset-specific rules: $d_{2,1}(\mathbf{h}_2)$ selects Trt c for \mathbf{h}_2 such that $r_2 = 0, a_1 = a$,

and $d_{2,2}(\mathbf{h}_2)$ selects Trt b for \mathbf{h}_2 such that $r_2 = 1, a_1 = a$. Thus, $I\{A_2 = d_2(\mathbf{H}_2)\} = R_2 I(A_2 = b) + (1 - R_2) I(A_2 = c)$, and $\omega_2\{\mathbf{H}_2, d_2(\mathbf{H}_2)\} = R_2 P(A_2 = b|A_1 = a, R_2 = 1, \kappa = 2) + (1 - R_2) P(A_2 = c|A_1 = a, R_2 = 0, \kappa = 2)$, where $P(A_2 = a_2|A_1 = a, R_2 = r, \kappa = 2)$ is the probability of being randomized to Trt a_2 at stage 2 after being randomized to Trt a at stage 1 and reaching stage 2 as a responder ($r = 1$) or nonresponder ($r = 0$). Then if $\kappa = 2$, for $u \geq 0$, $C(u, d) = I(A_1 = a) [I\{\mathcal{T}_2 > u\} + I\{\mathcal{T}_2 \leq u\} \{R_2 I(A_2 = b) + (1 - R_2) I(A_2 = c)\}]$ and $\pi(u, d) = P(A_1 = a) [I\{\mathcal{T}_2 > u\} + I\{\mathcal{T}_2 \leq u\} \{R_2 P(A_2 = b|A_1 = a, R_2 = 1, \kappa = 2) + (1 - R_2) P(A_2 = c|A_1 = a, R_2 = 0, \kappa = 2)\}]$.

Denote the survival function for censoring under the noninformative censoring assumption as $K_c\{u|H(u)\} = \exp[-\int_0^u \lambda_c\{s|H(s)\} ds]$, and define $N(u) = I(U \leq u, \Delta = 1)$ and $Y(u) = I(U \geq u)$. Then, under the above assumptions, we argue in Section A of the Appendix that an observed data analog to (5) is given by

$$\sum_{i=1}^n \sum_{j=1}^D \Omega_i(u, d^j) \{dN_i(u) - d\Lambda_0(u) Y_i(u)\} = 0, \quad \Omega(u, d) = \frac{C(u, d) I(U \geq u)}{\pi(u, d) K_c\{u|H(u)\}} w(u, d), \quad (10)$$

so that $d\hat{\Lambda}_0(u) = \{\sum_{i=1}^n \sum_{j=1}^D \Omega_i(u, d^j) dN_i(u)\} / \{\sum_{i=1}^n \sum_{j=1}^D \Omega_i(u, d^j) Y_i(u)\}$. Similarly, under H_0 , an analog to the “score equation” for β_j is $\sum_{i=1}^n \int_0^\infty \Omega_i(u, d^j) \{dN_i(u) - d\Lambda_0(u) Y_i(u)\}$, $j = 1, \dots, D - 1$, so that, substituting $d\hat{\Lambda}_0(u)$, the analog to (6) in terms of the observed data is the $(D - 1)$ -dimensional “score vector” $\mathfrak{T} = (\mathfrak{T}^1, \dots, \mathfrak{T}^{D-1})^T$, where

$$\mathfrak{T}^j = \sum_{i=1}^n \int_0^\infty \Omega_i(u, d^j) \{dN_i(u) - d\hat{\Lambda}_0(u) Y_i(u)\}, \quad j = 1, \dots, D - 1. \quad (11)$$

Although we have exemplified (8) and (9) in the context of SMARTs, where $\omega_k(\mathbf{h}_k, a_k)$, $k = 1, \dots, K$, are the known randomization probabilities used in the design at each stage, the formulation of (11) is valid if the data (7) arise from an observational study, in which case $\omega_k(\mathbf{h}_k, a_k)$ are likely unknown; see Section 2.3.

The quantity $\Omega(u, d)$ defined in (10) involves the censoring survival function $K_c\{u|H(u)\}$, a function of the history $H(u)$. Thus, in principle, censoring can depend on covariates and treatments received observed up to time u . As in a well-conducted conventional, single-

stage clinical trial and in Tsiatis et al. (2020, Section 8.3.3), censoring in a SMART may be primarily administrative, in which case it is reasonable to assume that, in addition to being noninformative in the sense defined above, censoring is independent of $H(u)$, and write $K_c(u)$. This assumption is analogous to that underlying the standard logrank test for a conventional multi-arm clinical trial, namely, that censoring is noninformative and independent of baseline covariates and treatment assignment. Under this condition, we can take $w(u, d^j) = K_c(u)$, $j = 1, \dots, D$, which leads to

$$\Omega(u, d^j) = \frac{C(u, d^j)I(U \geq u)}{\pi(u, d^j)}, \quad (12)$$

so that (11) and thus \mathfrak{T} does not depend on the censoring distribution. In fact, analogous to the usual logrank test, (12) holds if censoring depends only on stage 1 (baseline) treatment assignment, which we write as $K_c(u|a_1)$, and we take $w(u, d^j) = K_c(u|a^j)$, where a^j is the stage 1 treatment assigned by regime d^j . We assume henceforth that censoring is independent of $H(u)$ with the possible exception of stage 1 treatment and that $w(u, d)$ is specified so that (12) holds; more complex dependence on $H(u)$ is discussed in Section B of the Appendix.

In principle, a test statistic for H_0 can be constructed as a quadratic form in \mathfrak{T} depending on a (large-sample) approximation to the covariance matrix of \mathfrak{T} under H_0 . However, an obstacle to obtaining an approximate covariance matrix is that \mathfrak{T}^j in (11) for each $j = 1, \dots, D - 1$ and thus \mathfrak{T} is not a sum of independent and identically distributed (iid) mean-zero terms, so that standard asymptotic theory does not apply. Defining $d\bar{N}_i(u) = \sum_{j=1}^D \Omega_i(u, d^j)dN_i(u)$, $\bar{Y}_i(u) = \sum_{j=1}^D \Omega_i(u, d^j)Y_i(u)$, and $\hat{q}(u, d^j) = \{\sum_{i=1}^n \Omega_i(u, d^j)Y_i(u)\} / \sum_{i=1}^n \bar{Y}_i(u)$, we show in Section C of the Appendix that $n^{-1/2}$ times (11) can be written as

$$\begin{aligned} n^{-1/2}\mathfrak{T}^j = n^{-1/2} \sum_{i=1}^n \mathfrak{T}_i^j + o_p(1), \quad \mathfrak{T}_i^j = & \left[\int_0^\infty \Omega_i(u, d^j) \{dN_i(u) - d\Lambda_0(u)Y_i(u)\} \right. \\ & \left. - \sum_{j'=1}^D \int_0^\infty \Omega_i(u, d^{j'}) q(u, d^j) \{dN_i(u) - d\Lambda_0(u)Y_i(u)\} \right] \end{aligned} \quad (13)$$

where $q(u, d)$ is the limit in probability of $\hat{q}(u, d)$, so that $n^{-1/2}\mathfrak{T} = n^{-1/2} \sum_{i=1}^n \mathfrak{T}_i + o_p(1)$, $\mathfrak{T}_i = (\mathfrak{T}_i^1, \dots, \mathfrak{T}_i^{D-1})^T$, $i = 1, \dots, n$, and thus $n^{-1/2}\mathfrak{T}$ is asymptotically equivalent to $n^{-1/2}$

times a sum of mean-zero iid terms, and the asymptotic covariance matrix of $n^{-1/2}\mathfrak{T}$ can be approximated by $\Sigma = n^{-1} \sum_{i=1}^n (\mathfrak{T}_i \mathfrak{T}_i^T)$. Substituting $\hat{q}(u, d^j)$ for $q(u, d^j)$ and $d\hat{\Lambda}_0(u)$ for $d\Lambda_0(u)$ in (13), denoting the resulting approximation to \mathfrak{T}_i^j as $\hat{\mathfrak{T}}_i^j$, and letting $\hat{\mathfrak{T}}_i = (\hat{\mathfrak{T}}_i^1, \dots, \hat{\mathfrak{T}}_i^{D-1})^T$, Σ can be estimated by $\hat{\Sigma} = n^{-1} \sum_{i=1}^n (\hat{\mathfrak{T}}_i \hat{\mathfrak{T}}_i^T)$, yielding the test statistic $\mathbb{Z} = n^{-1} \mathfrak{T}^T \hat{\Sigma}^- \mathfrak{T}$, where $\hat{\Sigma}^-$ is a generalized inverse of $\hat{\Sigma}$. As in Wu, Wang, and Wahed (2023), we use a generalized inverse, as Σ and thus $\hat{\Sigma}$ may be singular due to a dependency structure in Σ induced by some SMART designs and the set of regimes of interest. E.g., for the SMART in Figure 2, if \mathcal{D} is the set of all $D = 8$ embedded regimes, the hazards for the four regimes starting with the same stage 1 treatment involve a linear dependency, so that Σ (7×7) has rank 5. In the SMART in Figure 3, ignoring the control, there is no such dependency, so if \mathcal{D} is the set of $D = 4$ embedded regimes, Σ is of full rank ($= 3$). In general, under H_0 , \mathbb{Z} has an approximate χ_ν^2 distribution with degrees of freedom $\nu = \text{rank}(\Sigma)$.

[Figure 3 about here.]

In (11) and (13), integration from 0 to ∞ implies that the range of integration is from 0 to at most the largest observed event time. In many studies, the number of subjects at risk at event times leading up to this time may be small; moreover, even fewer of these subjects may have treatment experience consistent with a particular regime. These features may lead to small numbers of subjects having undue influence on the test statistic. Thus, analogous to Kidwell and Wahed (2013), we recommend truncating the range of integration at a time L equal to or less than the largest observed event time. As a rule of thumb, we suggest choosing L so that 1% to 4% of subjects remain at risk at L .

2.3 Improving efficiency

In a SMART, the randomization probabilities $\omega_k(\mathbf{h}_k, a_k)$, $k = 1, \dots, K$, are known and are treated as known in the inverse probability weighting via (12) in the foregoing developments. However, although counterintuitive, it is well known (e.g., Tsiatis, 2006) that estimating

these probabilities can lead to more efficient inferences. Accordingly, we propose positing and fitting parametric models $\omega_k(\mathbf{h}_k, a_k; \boldsymbol{\gamma}_k)$, e.g., logistic models fitted by maximum likelihood (ML), yielding ML estimators $\hat{\boldsymbol{\gamma}}_k$. In a SMART, these models can be chosen so that the ML estimators for the randomization probabilities are the sample proportions of subjects randomized to each feasible treatment given their histories. E.g., in the SMART in Figure 2, for $a_1 = \text{Trt } 0$ and response status $r_2 = 1$, the estimator for the probability of being assigned to Trt 2 at stage 2 is the sample proportion subjects who received Trt 0, reached stage 2 as responders, and were assigned to Trt 2. In an observational study, the unknown $\omega_k(\mathbf{h}_k, a_k)$ must be modeled and fitted, typically via logistic regression/ML. We discuss modeling and fitting of $\omega_k(\mathbf{h}_k, a_k)$ in SMARTs and observational studies in Section B of the Appendix.

In Section D of the Appendix, following results in Tsiatis (2006), we present an argument demonstrating that, if the randomization probabilities in a SMART are modeled and estimated by ML as above and the fitted models $\omega_k(\mathbf{h}_k, a_k; \hat{\boldsymbol{\gamma}}_k)$, $k = 1, \dots, K$, are substituted in place of the known probabilities, as long as estimation of $\boldsymbol{\gamma} = (\boldsymbol{\gamma}_1^T, \dots, \boldsymbol{\gamma}_K^T)^T$ is taken into appropriate account in a modified test statistic, the resulting test of H_0 will be more powerful than that based on \mathbb{Z} . In an observational study, in which the $\omega_k(\mathbf{h}_k, a_k)$ are unknown and must be modeled and fitted, the argument also demonstrates how estimation of $\boldsymbol{\gamma}$ should be taken into account to lead to a test that is valid as long as the models are correctly specified.

The form of the modified test statistic follows from Section D of the Appendix and is given as follows. Let $\boldsymbol{\mathfrak{T}}(\hat{\boldsymbol{\gamma}})$ be $\boldsymbol{\mathfrak{T}}$ with the models $\omega_k(\mathbf{h}_k, a_k; \hat{\boldsymbol{\gamma}}_k)$, $k = 1, \dots, K$, fitted by ML substituted, and let $\boldsymbol{\Sigma}_\gamma$ be the asymptotic covariance matrix of $\boldsymbol{\mathfrak{T}}(\hat{\boldsymbol{\gamma}})$. Let $\boldsymbol{S}_\gamma(\boldsymbol{\gamma})$ be the score vector associated with $\boldsymbol{\gamma}$; i.e., the vector of partial derivatives with respect to $\boldsymbol{\gamma}$ of the loglikelihood associated with $\boldsymbol{\gamma}$ for the posited models. See Section D of the Appendix for examples of the form of $\boldsymbol{S}_\gamma(\boldsymbol{\gamma})$. For $j = 1, \dots, D - 1$, let $\hat{\boldsymbol{\mathfrak{T}}}_i^j(\hat{\boldsymbol{\gamma}})$, $i = 1, \dots, n$, denote $\hat{\boldsymbol{\mathfrak{T}}}_i^j$ as defined above with the fitted models $\omega_k(\mathbf{h}_k, a_k; \hat{\boldsymbol{\gamma}}_k)$, $k = 1, \dots, K$, substituted. For each

$j = 1, \dots, D - 1$, carry out a linear regression of the $\widehat{\mathfrak{T}}_i^j(\widehat{\gamma})$ on $\mathbf{S}_{\gamma,i}(\widehat{\gamma})$ and form for subjects $i = 1, \dots, n$ the residuals from this fit, which we denote as $\widehat{\mathfrak{T}}_i^{j,R}(\widehat{\gamma})$, $i = 1, \dots, n$. Then we show in Section D of the Appendix that, letting $\widehat{\mathfrak{T}}_i^R(\widehat{\gamma}) = \{\widehat{\mathfrak{T}}_i^{1,R}(\widehat{\gamma}), \dots, \widehat{\mathfrak{T}}_i^{D-1,R}(\widehat{\gamma})\}^T$, the estimator for Σ_γ is given by $\widehat{\Sigma}_\gamma = n^{-1} \sum_{i=1}^n \{\widehat{\mathfrak{T}}_i^R(\widehat{\gamma}) \widehat{\mathfrak{T}}_i^R(\widehat{\gamma})^T\}$, and the modified test statistic is constructed as $\mathbb{Z}(\widehat{\gamma}) = n^{-1} \widehat{\mathfrak{T}}^R(\widehat{\gamma})^T \widehat{\Sigma}_\gamma^{-1} \widehat{\mathfrak{T}}^R(\widehat{\gamma})$, where $\widehat{\mathfrak{T}}^R(\widehat{\gamma}) = \sum_{i=1}^n \widehat{\mathfrak{T}}_i^R(\widehat{\gamma})$. We also present an argument that, asymptotically, the test of H_0 based on $\mathbb{Z}(\widehat{\gamma})$ is at least as powerful as that based on \mathbb{Z} . As above, truncation of integration at some value L should also be implemented.

In fact, as we discuss in Section D of the Appendix, if there are components of the history at any decision point that are associated with the outcome, it is possible to obtain an even more powerful test by exploiting these associations. The associated test statistic is obtained by regressing the $\widehat{\mathfrak{T}}_i^j(\widehat{\gamma})$, $i = 1, \dots, n$, not only on $\mathbf{S}_{\gamma,i}(\widehat{\gamma})$ but also on suitably chosen functions of the histories at each decision point to obtain the residuals $\widehat{\mathfrak{T}}_i^{j,R}(\widehat{\gamma})$, $i = 1, \dots, n$. Only components of the history thought to be strongly associated with the outcome should be incorporated, as including components that are only weakly associated could degrade performance if n is not large. See Section D of the Appendix for a demonstration and further discussion.

When n is not large, any of the proposed tests based on \mathbb{Z} or $\mathbb{Z}(\widehat{\gamma})$ can be anticonservative; i.e., reject H_0 too often, leading to inflated type I error. This behavior is due to the fact that the estimator $\widehat{\Sigma}$ or $\widehat{\Sigma}_\gamma$, as appropriate, understates the uncertainty in the components of \mathfrak{T} or $\mathfrak{T}(\widehat{\gamma})$, which is not uncommon with methods based on semiparametric theory. In Section E of the Appendix, we propose a bias correction to $\widehat{\Sigma}$ and $\widehat{\Sigma}_\gamma$ that, when the bias-corrected covariance matrix is used to form the test statistic, yields a test that more closely achieves the nominal level of significance. In the simulations in Section 3, we demonstrate that such anticonservatism is ameliorated when the bias correction is used.

2.4 Comparison to existing methods

Kidwell and Wahed (2013) and Li et al. (2014) were the first to propose logrank-type tests for comparing regimes, including “shared path” regimes, on the basis of a time-to-event outcome. The approach of Kidwell and Wahed (2013) is restricted to SMARTs with $K = 2$ stages analogous to that in Figure 3 without the control regime and focuses on the four embedded regimes. The approach of Li et al. (2014) allows the data to arise from an observational study and in principle can be applied to settings with any number of decision points, although it is formulated and evaluated only in a two-stage observational setting analogous to the four-regime SMART considered by Kidwell and Wahed (2013) and for regimes of the form, e.g., with $K = 2$, “Give a_1 ; if response give a_2 , otherwise continue a_1 .” Of necessity, modeling and fitting of $\omega_k(\mathbf{h}_k, a_k)$, $k = 1, \dots, K$, is required. Both approaches do not support incorporation of covariate information to improve power and assume that censoring is noninformative and independent of $H(u)$.

Our motivation for developing the proposed methods is to provide a unified framework for general K in which comparison of the regimes in an entirely arbitrary set of regimes of interest within the class of “feasible regimes” given the available data (Tsiatis et al., 2020, Section 6.2.3) can be carried out based on data from a SMART or observational study and that allows consideration of censoring mechanisms beyond independent censoring, as might be expected with observational data. We focus primarily on SMARTs and independent censoring in this article. The “score vector” on which the test statistic of Li et al. (2014) is based is equivalent to our \mathfrak{T} comprising elements in (11) with $w(u, d^j) = K_c(u)$, $j = 1, \dots, D$, as in (12); because the Li et al. (2014) formulation does not include a weight function analogous to $w(u, d)$, generalization to censoring mechanisms other than noninformative, independent censoring as in Section B of the Appendix is not accommodated. Regarding the covariance matrix used to form the test statistic of Li et al. (2014), the authors contend,

contrary to the results in Section 2.3, that, in our notation, estimation of γ in models $\omega_k(\mathbf{h}_k, a_k; \gamma_k)$, $k = 1, \dots, K$, does not have an effect on the asymptotic distribution of the test statistic, so that no account need be taken of estimation of γ . In Section D of the Appendix, we show that there is a misstatement in the proof that Li et al. (2014) present to justify this claim. Thus, their test statistic as proposed, which uses a covariance matrix that does not take account of this estimation, is expected to be conservative, as seen in their simulations, where it rejects H_0 at a rate lower than the nominal level for even very large sample sizes.

The test of Kidwell and Wahed (2013) is based on a vector of pairwise comparisons of the hazards corresponding to three of the embedded regimes against a fourth reference regime, where known randomization probabilities are used. Derivation of the covariance matrix of this vector used to form the authors' proposed test statistic is based on counting process martingale theory. However, as we discuss in Section D of the Appendix, the components of the vector need not be martingales with respect to the filtration given by Kidwell and Wahed (2013). Thus, although the vector has mean zero and is asymptotically normal, the authors' covariance formula derived from this perspective may be biased for the true sampling covariance matrix. In simulations, we have observed that the extent to which this feature may impact inferences is dependent on the data generative scenario: as shown in Section 3, depending on the scenario, the test may be robust to this feature or may not achieve the nominal level of significance even for large sample sizes.

3. Simulation studies

We present results of a suite of simulation studies, each with 5000 Monte Carlo data sets, under several data generative scenarios and SMART designs with $K = 2$. For each scenario, we evaluate type I error under H_0 in (1) and power under alternatives to H_0 for level of significance 0.05 using the test statistic of Kidwell and Wahed (2013), Z_{KW} , say, where

applicable, and several versions of the proposed test statistic with estimated randomization probabilities, $\mathbb{Z}(\hat{\gamma})$, denoted as $\mathbb{Z}_{U,\text{nocov}}$ and $\mathbb{Z}_{C,\text{nocov}}$ without incorporation of covariates using the uncorrected and bias-corrected versions of the covariance matrix $\hat{\Sigma}_{\gamma}$, respectively; and as $\mathbb{Z}_{U,\text{cov}}$ and $\mathbb{Z}_{C,\text{cov}}$, which do incorporate covariates.

Scenarios 1 and 2 involve a SMART as in Figure 3 without the control regime, so with four embedded regimes, and use the generative process of Kidwell and Wahed (2013), modified to possibly involve covariates. We first generated baseline covariate $X_1 \sim \mathcal{N}(0, 1)$ and stage 1 treatment A_1 as Bernoulli(0.5). We then generated response status R as Bernoulli(0.4); and, if $R = 1$, intermediate covariate X_2 as Bernoulli(p_{X_2}), where, for $\boldsymbol{\theta}_{X_2} = (\theta_{X_2,1}, \theta_{X_2,2}, \theta_{X_2,3})^T$, $p_{X_2} = \text{expit}(\theta_{X_2,1} + \theta_{X_2,2}X_1 + \theta_{X_2,3}A_1)$ and $\text{expit}(u) = e^u/(1 + e^u)$, and A_2 as Bernoulli(0.5), so that $\mathbf{X}_2 = (R, X_2)^T$. Then, given $\boldsymbol{\theta} = (\theta_1^{NR}, \theta_0^{NR}, \theta_1^R, \theta_0^R, \theta_{11}^{RE}, \theta_{10}^{RE}, \theta_{01}^{RE}, \theta_{00}^{RE})^T$, $\boldsymbol{\delta}^{NR} = (\delta_1^{NR}, \delta_0^{NR})^T$, $\boldsymbol{\delta}^R = (\delta_1^R, \delta_0^R)^T$, $\boldsymbol{\alpha}_{\ell} = (\alpha_{\ell,11}, \alpha_{\ell,10}, \alpha_{\ell,01}, \alpha_{\ell,00})^T$, $\ell = 1, 2$, with $\lambda_r^{NR} = \theta_r^{NR} \exp(\delta_r^{NR} X_1)$, $\lambda_r^R = \theta_r^R \exp(\delta_r^R X_1)$, $r = 0, 1$, and $\lambda_{rs}^{RE} = \theta_{rs}^{RE} \exp\{\alpha_{1,rs} X_1 + \alpha_{2,rs}(X_2 - p_{X_2})\}$, $r, s = 0, 1$, for $R = 0$, we generated potential event times T_r^{NR} , $r = 0, 1$, as $\text{exponential}(\lambda_r^{NR})$; and, for $R = 1$, potential times to response T_r^R , $r = 0, 1$, as $\text{exponential}(\lambda_r^R)$ and times from response to event T_{rs}^{RE} as $\text{exponential}(\lambda_{rs}^{RE})$, $r, s = 0, 1$. With $T^{NR} = A_1 T_1^{NR} + (1 - A_1) T_0^{NR}$ for $R = 0$ and $T^R = A_1 \{A_2(T_1^R + T_{11}^{RE}) + (1 - A_2)(T_1^R + T_{10}^{RE})\} + (1 - A_1) \{A_2(T_0^R + T_{01}^{RE}) + (1 - A_2)(T_0^R + T_{00}^{RE})\}$ for $R = 1$, the event time was $T = RT^R + (1 - R)T^{NR}$. Censoring time C was generated as $\text{uniform}(0, c_{\max})$, and $U = \min(T, C)$, $\Delta = I(T \leq C)$. If the event time was censored prior to response, we redefined $R = 0$. Thus, for $R = 1$, the time to Decision 2 $\mathcal{T}_2 = A_1 T_1^R + (1 - A_1) T_0^R$ and $\kappa = 2$, and, as nonresponders never reach Decision 2, $\kappa = 1$ for $R = 0$.

In Scenario 1, we took $c_{\max} = 3.80$, resulting in 30% to 40% censoring. Under H_0 , Scenario 1(a) takes $\boldsymbol{\theta} = (1/0.91, 1/0.91, 1/0.5, 1/0.5, 1, 1, 1, 1)^T$, with $\boldsymbol{\theta}_{X_2}$, $\boldsymbol{\delta}^R$, $\boldsymbol{\delta}^{NR}$, $\boldsymbol{\alpha}_{\ell}$, $\ell = 1, 2$, vectors of zeroes, so that time to event is not associated with covariates, and thus duplicates the first null hypothesis scenario of Kidwell and Wahed (2013). Scenario 1(b) is the same

but with covariate associations induced by taking $\boldsymbol{\theta}_{X_2} = (0, 0.15, 0)^T$, $\boldsymbol{\delta}^R = (0.7, 0.7)^T$, $\boldsymbol{\delta}^{NR} = (0.3, 0.3)^T$, $\boldsymbol{\alpha}_\ell = (0.7, 0.7, 0.7, 0.7)^T$, $\ell = 1, 2$. In Table 1, under both 1(a) and 1(b), all tests are anti-conservative for $n = 250$. Those based on $\mathbb{Z}_{C,\text{nocov}}$, $\mathbb{Z}_{C,\text{cov}}$, and \mathbb{Z}_{KW} achieve the nominal level for $n = 500, 1000$; including unimportant covariates as in 1(a) does not degrade performance. The tests based on $\mathbb{Z}_{U,\text{nocov}}$ and $\mathbb{Z}_{U,\text{cov}}$ are anti-conservative, supporting use of the bias correction. As an alternative to H_0 under 1(b), we took $\boldsymbol{\theta} = (1/0.91, 1/1.15, 1/0.9, 1/0.5, 1/2, 1/2.33, 1/1.11, 1/0.67)^T$, with all other quantities the same. From Table 1, for tests that achieve the nominal level under H_0 , incorporation of covariates associated with the event time using the proposed methods yields increases in power.

As discussed in Section F of the Appendix, the test of Kidwell and Wahed (2013) may be expected to be robust to departure from the martingale property under Scenario 1. Under H_0 , Scenarios 2(a) and 2(b) are the same as 1(a) and 1(b) except with $c_{\max} = 8$, resulting in 25% to 30% censoring, and $\boldsymbol{\theta} = (1/0.91, 1/0.91, 1/0.5, 1/0.5, 1/3, 1/3, 1/3, 1/3)^T$. As Table 1 shows, all tests are anti-conservative with $n = 250$; however, for $n = 500, 1000$, the tests based on $\mathbb{Z}_{C,\text{nocov}}$ and $\mathbb{Z}_{C,\text{cov}}$ achieve the nominal level, while those based on \mathbb{Z}_{KW} continue to be anti-conservative. In Section F of the Appendix, we speculate that this behavior may reflect a strong departure from the martingale property for these Scenarios. For an alternative to Scenario 2(b), we took instead $\boldsymbol{\theta} = (1/0.35, 1/0.9, 1/0.5, 1/0.5, 1/3.3, 1/3.3, 1/3, 1/3)^T$; again, Table 1 shows gains in power when associated covariates are incorporated in the proposed methods.

Scenario 3 uses a different generative strategy and mimics the design of Study C9710. We first generated $\mathbf{X}_1 = (X_{11}, X_{12})^T$, where $X_{11} \sim \mathcal{N}(0, 1)$ and $X_{12} \sim \text{uniform}(0, 1)$, and A_1 as Bernoulli(0.5). For given α_{1D} , α_{1SS} , α_{2AL} , ψ , and ζ , we took $\boldsymbol{\theta}_{1D} = (\alpha_{1D}, 0.5\psi, 0.5\psi, -0.26\zeta)^T$ and $\boldsymbol{\theta}_{1SS} = (\alpha_{1SS}, 0.5\psi, 0.5\psi, 0.24\zeta)^T$, generated potential event time T_D as $\text{exponential}(\lambda_{1D})$, $\lambda_{1D} = \exp\{\theta_{1D,1} + \theta_{1D,2}X_{11} + \theta_{1D,3}(X_{12} - 0.5) + \theta_{1D,4}(A_1 - 0.5)\}$ and potential time to Decision

$2 T_{SS}$ as exponential(λ_{1SS}), $\lambda_{1SS} = \exp\{\theta_{1SS,1} + \theta_{1SS,2}X_{11} + \theta_{1SS,3}(X_{12} - 0.5) + \theta_{1SS,4}(A_1 - 0.5)\}$, and took $S = \min(T_D, T_{SS})$, $R = I(T_{SS} < T_D)$. If $R = 1$, with $\theta_{X_2} = (0.2, 0.5\psi, 0.4\psi, 0.12\zeta)^T$ and $\theta_{2AL} = (\alpha_{2AL}, 0.5\psi, -0.52\psi, 0.6\psi, -0.1\zeta, -0.11\zeta)^T$, we generated X_2 as Bernoulli(p_{X_2}), $p_{X_2} = \text{expit}(\theta_{X_2,1} + \theta_{X_2,2}X_{11} + \theta_{X_2,3}X_{12} + \theta_{X_2,4}A_1)$, A_2 as Bernoulli(0.5), and “added life” post-response T_{AL} as exponential($\lambda_{2,AL}$), $\lambda_{1AL} = \exp\{\theta_{1AL,1} + \theta_{1AL,2}X_{11} + \theta_{1AL,3}(X_{12} - 0.5) + \theta_{1AL,4}(X_2 - p_{X_2}) + \theta_{1AL,5}(A_1 - 0.5) + \theta_{1AL,6}(A_2 - 0.5)\}$. We then took $T = (1 - R)T_D + R(T_{SS} + T_{AL})$ and, with C uniform(0, c_{\max}), $U = \min(T, C)$, $\Delta = I(T \leq C)$; if $R = 1$ and $C < T_{SS}$, redefine $R = 0$. For $R = 1$, $\mathcal{T}_2 = T_{SS}$ and $\kappa = 2$; else, $\kappa = 1$.

Scenarios 3(a) - 3(c) reflect different possible departures from the martingale property through specification of α_{1D} and α_{2AL} ; the property roughly holds with $\alpha_{1D} = \alpha_{2AL}$. In all cases, $\alpha_{1SS} = -4.2$, $\psi = 1.5$, and $\zeta = 0$ corresponds to H_0 while $\zeta > 0$ produces alternatives to H_0 . For Scenarios 3(a) and 3(b), $c_{\max} = 500$, resulting in about 40% to 45% censoring; for Scenario 3(c), $c_{\max} = 300$ for about 30% censoring. For Scenario 3(a), $\alpha_{1D} = \alpha_{2AL} = -5.5$; from Table 1, under H_0 , the tests based on $\mathbb{Z}_{C,\text{nocov}}$, $\mathbb{Z}_{C,\text{cov}}$, and \mathbb{Z}_{KW} all achieve the nominal level, and incorporation of covariates yields increased power under alternatives. Under Scenarios 3(b) and 3(c), $\alpha_{1D} = -4.5$, $\alpha_{1AL} = -5.5$ and $\alpha_{1D} = -5.5$, $\alpha_{1AL} = -3.5$, respectively. While the tests based on $\mathbb{Z}_{C,\text{nocov}}$ and $\mathbb{Z}_{C,\text{cov}}$ achieve the nominal level under H_0 in both cases for all n , that based on \mathbb{Z}_{KW} is conservative under 3(b) and anti-conservative under 3(c), which persists across all n , possibly reflecting departure from the martingale property; see Section F of the Appendix.

Scenarios 4 and 5 involve data generative strategies similar to those for Scenario 3; details are in Section F of the Appendix. Scenario 4 includes an additional control arm as in Figure 3, so that $\mathcal{A}_1 = \{0, 1, \text{control}\}$, with equal randomization to treatments 0, 1 and control (i.e., randomization probability 1/3 for each) at Decision 1 and randomization probability 0.5 to each treatment option at Decision 2. Scenario 5 follows a design like that in Figure 2, with

eight embedded regimes and randomization probabilities of 0.5 for each treatment option in each feasible set at each decision point. Thus, in both scenarios, the test of Kidwell and Wahed (2013) is not applicable. Under H_0 , the proposed tests using the bias-corrected version of $\widehat{\Sigma}_\gamma$ achieve the nominal level in all cases, and under alternatives to H_0 , incorporation of covariates associated with the time-to-event outcome leads to gains in power.

The foregoing results focus on comparison of the hazard rates associated with all embedded regimes represented in a SMART. A secondary analysis of interest in many SMARTs is comparison of specific pairs of embedded regimes, e.g., the most and least resource intensive or burdensome or each embedded regime against a control regime in SMARTs like that in Figure 3. In Section F of the Appendix, we report on simulation studies of the performance of the proposed tests and, where applicable, that of tests based on the statistic of Kidwell and Wahed (2013), for comparing the hazards for pairs of embedded regimes, including “shared path” regimes. An additional analysis of interest in some SMARTs is to compare more complex “feasible regimes” with rules depending on covariate information; we report on a simulation study using the proposed methods for this purpose in Section F of the Appendix.

[Table 1 about here.]

4. Application to Study C9710

As in Section 1, Study C9710 is a SMART with $K = 2$ decision points. At Decision 1, $\mathcal{A}_1 = \{0, 1\}$, where 0 (1) corresponds to ATRA (ATRA + arsenic trioxide) consolidation therapy; at Decision 2, $\mathcal{A}_2 = \{0, 1\}$, where 0 (1) corresponds to ATRA (ATRA+Mtx+MP) maintenance therapy. Only subjects who did not experience the event or for whom the event was not censored before the end of consolidation, referred to as “responders,” with $\kappa = 2$, were randomized to maintenance therapy. Section G of the Appendix provides details of the data, which involve $n = 467$ subjects, of which 310 were responders ($\kappa = 2$) and

157 experienced the event of censoring before completing consolidation ($\kappa = 1$). Baseline covariate \mathbf{X}_1 comprises ten variables, and the additional information collected between study entry and stage 2, \mathbf{X}_2 , includes 46 variables indicating adverse events arising during induction and/or consolidation therapy; see Section G of the Appendix. Equal randomization was used at both decisions, i.e., $\omega_1(\mathbf{h}_1, a_1) = 1/2$ for all \mathbf{h}_1 and $a_1 \in \mathcal{A}_1$, and $\omega_2(\mathbf{h}_2, a_2) = 1/2$ for all \mathbf{h}_2 , $a_2 \in \mathcal{A}_2$, and $\kappa = 2$. As in Section 2.3 and shown in Section G of the Appendix, we specified models $\omega_k(\mathbf{h}_k, a_k; \gamma_k)$, $k = 1, 2$, and fitted these by ML to obtain estimated randomization probabilities. The maximum follow-up time is 4694 days, with maximum time to EFS of 4000; in all analyses, we took $L = 4200$, resulting in about 2% truncation.

As in Figure 1, the study involves four embedded regimes of the form “Give consolidation therapy a ; if subject completes consolidation before the event occurs, give maintenance therapy b ,” which we denote as Regimes 1, 2, 3, and 4 as $(a, b) = (0, 0), (0, 1), (1, 0), (1, 1)$. To visualize the survival functions $\mathcal{S}(u, d^j) = P\{T^*(d^j) \geq u\}$ corresponding to Regimes $j = 1, \dots, 4$, we estimated the cumulative hazard functions $\Lambda(u, d^j) = \int_0^u \lambda(u, d^j) du$ by $\hat{\Lambda}(u, d^j) = \int_0^u \{ \sum_{i=1}^n \Omega_i(u, d^j) dN_i(u) / \sum_{i=1}^n \Omega_i(u, d^j) Y_i(u) \}$, with estimated randomization probabilities substituted, obtaining estimates $\hat{\mathcal{S}}(u, d^j) = \exp\{-\hat{\Lambda}(u, d^j)\}$. Figure 4 depicts $\hat{\mathcal{S}}(u, d^j)$, $j = 1, \dots, 4$, and suggests that administering ATRA + arsenic trioxide ($a_1 = 1$) initially, as in Regimes 3 and 4, is more beneficial than administering ATRA alone as in Regimes 1 and 2, consistent with the findings of Powell et al. (2010). The estimates suggest further that, of the regimes starting with ATRA + arsenic trioxide, Regime 4, which gives ATRA+Mtx+MP maintenance to responders, may yield benefit over Regime 3.

[Figure 4 about here.]

Table 2 shows the results of tests of H_0 in (1) corresponding to different choices of the set \mathcal{D} of regimes of interest. We tested H_0 several ways: using (i) the proposed test statistic $\mathbb{Z}(\hat{\gamma})$ with estimated randomization probabilities and using the bias correction to

$\widehat{\Sigma}_\gamma$, without incorporation of covariates, denoted $\mathbb{Z}_{C,\text{nocov}}$ as in Table 1; (ii) same as (i) but incorporating selected baseline covariates in \mathbf{X}_1 , namely, logarithm of white blood cell count and ECOG performance status, and intermediate adverse events in \mathbf{X}_2 , nausea and hemorrhage/bleeding (see Section G of the Appendix), denoted $\mathbb{Z}_{C,\text{cov}}$; and (iii) the test statistic of Kidwell and Wahed (2013), denoted \mathbb{Z}_{KW} (which uses known randomization probabilities). P-values for each test were obtained from the appropriate χ^2 distribution. With $\mathcal{D} = \{d^1, d^2, d^3, d^4\}$, $D = 4$, the set of all embedded regimes, all tests strongly reject H_0 , consistent with the evidence in Figure 4. We also took \mathcal{D} with $D = 2$ to obtain pairwise comparisons; because the components of the test statistic of Kidwell and Wahed (2013) address pairwise comparisons (see Section F of the Appendix), \mathbb{Z}_{KW} in Table 2 represents tests based on (linear combinations of) the relevant components. In all cases, the proposed test statistics incorporating covariates yield the largest value, consistent with the expected increase in power. For the key pairwise comparison of “shared path” regimes 3 and 4 starting with ATRA + arsenic trioxide, the proposed test statistics yield evidence of a difference (without adjustment for multiple comparisons) supporting further investigation of the use of ATRA+Mtx+MP as maintenance following this consolidation therapy.

[Table 2 about here.]

5. Discussion

We have proposed a general statistical framework in which we have developed a logrank-type test that can be used to compare the survival distributions of a time-to-event outcome were the patient population to receive treatment according to each treatment regime within a specified set of regimes based on the data from a SMART with an arbitrary number of stages. The test statistic can be modified to incorporate covariate information to enhance efficiency, and the test can also be conducted based on data from a longitudinal observational study,

although we have focused on its use in SMARTs here. The set of regimes of interest can be the set of regimes embedded in a SMART, a subset of these regimes, or an arbitrary set of regimes, where each regime in the set is “feasible” given the available data in the sense discussed in Tsiatis et al. (2020, Section 6.2.3). The test is valid under assumptions analogous to those underlying the standard logrank test for comparing single-stage treatments. Our simulations demonstrate that the test procedure achieves the nominal level under null hypotheses and that incorporation of covariates associated with the outcome leads to increases in power.

Appendix

A. Representation in Terms of Observed Data

We wish to show that, under H_0 and the identifiability assumptions in Section 2.2, for $u \geq 0$, an inverse probability weighted observed data analog to (5), that is,

$$\sum_{i=1}^n \sum_{j=1}^D w(u, d^j) \{dN_i^*(u, d^j) - d\Lambda_0(u)Y_i^*(u, d^j)\} = 0, \quad (\text{A.1})$$

is given by (10),

$$\sum_{i=1}^n \sum_{j=1}^D \Omega_i(u, d^j) \{dN_i(u) - d\Lambda_0(u)Y_i(u)\} = 0, \quad \Omega(u, d) = \frac{C(u, d)I(U \geq u)}{\pi(u, d)K_c\{u|H(u)\}}w(u, d), \quad (\text{A.2})$$

and that the “score equation” for β_j in terms of potential outcomes,

$$\sum_{i=1}^n \int_0^\infty w(u, d^j) \{dN_i^*(u, d^j) - d\Lambda_0(u)Y_i^*(u, d^j)\} = 0, \quad (\text{A.3})$$

has observed data analog

$$\sum_{i=1}^n \int_0^\infty \Omega_i(u, d^j) \{dN_i(u) - d\Lambda_0(u)Y_i(u)\} = 0 \quad (\text{A.4})$$

for $j = 1, \dots, D-1$. Multiplying (A.1)-(A.4) by n^{-1} , it suffices to show that the limit in probability of (A.1) is the same as that for (A.2), and similarly for (A.3) and (A.4). Because the weights $w(u, d^j)$, $j = 1, \dots, D-1$, are fixed constants for each u and d^j , we disregard them and thus show that, similar to Tsiatis et al. (2020, Section 8.4.3) and using the definition of $\Omega(u, d)$ in (A.2), for regime d ,

$$E \left[\frac{C(u, d)I(U \geq u)}{\pi(u, d)K_c\{u|H(u)\}} \{dN(u) - d\Lambda_0(u)Y(u)\} \right] = E \{dN^*(u, d) - d\Lambda_0(u)Y^*(u, d)\}.$$

Clearly, it suffices to show that

$$E \left[\frac{C(u, d)I(U \geq u)}{\pi(u, d)K_c\{u|H(u)\}} \{dN(u) - d\Lambda_0(u)Y(u)\} \middle| \mathcal{W}^* \right] = dN^*(u, d) - d\Lambda_0(u)Y^*(u, d). \quad (\text{A.5})$$

The integrand on the left hand side of (A.5) can be written as

$$\frac{C(u, d)I(U \geq u)}{\pi(u, d)K_c\{u|H(u)\}} I(U \geq u) \{dN(u) - d\Lambda_0(u)Y(u)\}.$$

By the consistency assumption, this expression can then be written as

$$\begin{aligned} & \frac{C(u, d)I(U \geq u)}{\pi(u, d)K_c\{u|H(u)\}} \{dN^*(u, d) - d\Lambda_0(u)Y^*(u, d)\} \\ &= \frac{C(u, d)I(U \geq u)}{\pi(u, d)K_c\{u|H(u)\}} I\{T^*(d) \geq u\} \{dN^*(u, d) - d\Lambda_0(u)Y^*(u, d)\}, \end{aligned}$$

so that the left hand side of (A.5) becomes

$$\{dN^*(u, d) - d\Lambda_0(u)Y^*(u, d)\} E \left[\frac{C(u, d)I(U \geq u)}{\pi(u, d)K_c\{u|H(u)\}} \middle| \mathcal{W}^*, T^*(d) \geq u \right]. \quad (\text{A.6})$$

Thus, from (A.6), we need to show that

$$E \left[\frac{C(u, d)I(U \geq u)}{\pi(u, d)K_c\{u|H(u)\}} \middle| \mathcal{W}^*, T^*(d) \geq u \right] = 1, \quad u \geq 0. \quad (\text{A.7})$$

We argue heuristically that (A.7) holds using a discrete time approximation and induction. Assume that, rather than occurring at any point in continuous time, decision points can occur only at equally-spaced time points; e.g., at any whole second, but not at fractions of a second. Partition the interval $[0, u]$ into an equally-spaced grid with grid points v_m , $m = 0, \dots, M$, where $v_0 = 0$ and $v_M = u$, such that any decision points occurring in the interval $[0, u]$ fall on the grid, and intervals between grid points are of length $\delta v = u/M$. Define $A(v_m)$ to be the treatment option that is received at time v_m from among the feasible options at v_m . If v_m corresponds to one of the times $\mathcal{T}_1, \dots, \mathcal{T}_\kappa$ at which decision points are reached, then $A(v_m)$ is the treatment assigned at v_m ; if v_m does not correspond to one these times, then $A(v_m)$ is equal to the sole option “do nothing.” Let $H^-(v_m)$ to be the history through time v_m up to but not including $A(v_m)$; i.e., $H^-(v_m)$ comprises all prior covariate information, treatments, and times of decision points up to and including v_m that would be used to determine treatment if v_m were a decision point. Thus, with $H(u)$ defined as in the main

paper, $H(v_m) = \{H^-(v_m), A(v_m)\}$. Then, for the regime d of interest, define $d\{H^-(v_m)\}$ to be the “rule” that assigns treatment at time v_m based on the history $H^-(v_m)$ at time v_m ; if v_m corresponds to one of these times, $d\{H^-(v_m)\}$ assigns the treatment indicated by the relevant rule in d given the history; if not, $d\{H^-(v_m)\}$ assigns “do nothing.” Define the following quantities:

$$C^M(u, d) = \prod_{m=0}^M I[A(v_m) = d\{H^-(v_m)\}]$$

$$\pi^M(u, d) = \prod_{m=0}^M P[A(v_m) = d\{H^-(v_m)\} | H^-(v_m), U \geq v_m]$$

$$K_c^M\{u | H(u)\} = \prod_{m=0}^M P\{U \geq v_{m+1} | H^-(v_m), A(v_m), U \geq v_m, T^*(d) \geq u\} \quad (\text{A.8})$$

$$= \prod_{m=0}^M P\{U \geq v_{m+1} | H(v_m), U \geq v_m, T^*(d) \geq u\} \quad (\text{A.9})$$

$$I^M(u) = \prod_{m=0}^M I(U \geq v_{m+1}). \quad (\text{A.10})$$

In (A.9) and (A.10), v_{M+1} is the next time point outside of the interval $[0, u]$, i.e., $u + \delta u = u(1 + 1/M)$. Evidently, $C^M(u, d) = C(u, d)$ and $\pi^M(u, d) = \pi(u, d)$. In (A.9), when $T^*(d) \geq u$,

$$\begin{aligned} P\{U \geq v_{m+1} | U \geq v_m, H(v_m), T^*(d) \geq u\} \\ = 1 - P\{v_m \leq U < v_{m+1} | U \geq v_m, H(v_m), T^*(d) \geq u\}. \end{aligned} \quad (\text{A.11})$$

Because $v_m \leq u$, $m = 0, \dots, M$ and $T^*(d) \geq u$, the only way that U can fall between v_m and v_{m+1} for $m = 0, \dots, M - 1$ is if an individual is censored, in which case (A.11) becomes

$$1 - P\{v_m \leq U < v_{m+1}, \Delta = 0 | U \geq v_m, H(v_m), T^*(d) \geq u\}. \quad (\text{A.12})$$

For $m = M$, the probability in (A.11) converges to 0 as $M \rightarrow \infty$. Thus, with the assumption of noninformative censoring, (A.12) is approximately equal to $1 - \lambda_c\{v_m | H(v_m)\}\delta v$, so that

$$K_c^M\{u | H(u)\} \approx \exp \left[- \int_0^u \lambda_c\{v | H(v)\} dv \right] = K_c\{u | H(u)\}$$

for large M . Likewise, if U is continuous, $I^M(u)$ converges almost surely to $I(U \geq u)$ as $M \rightarrow \infty$.

Now define the sequence of random variables

$$\mathcal{Z}^M = \frac{C^M(u, d)I^M(u)}{\pi^M(u, d)K_c^M\{u|H(u)\}}.$$

From the considerations above, under reasonable regularity conditions, \mathcal{Z}^M converges almost surely as $M \rightarrow \infty$ to

$$\frac{C(u, d)I(U \geq u)}{\pi(u, d)K_c\{u|H(u)\}}.$$

Thus, if we can show that

$$E\{\mathcal{Z}^M|\mathcal{W}^*, T^*(d) \geq u\} = 1 \text{ a.s.}, \quad (\text{A.13})$$

then under regularity conditions the desired result (A.7) holds.

We demonstrate (A.13) by induction. Specifically, define the partial products

$$\mathcal{Z}^M(t) = \prod_{m=0}^t \frac{I[A(v_m) = d\{H^-(v_m)\}]I(U \geq v_{m+1})}{P[A(v_m) = d\{H^-(v_m)\}|H^-(v_m), U \geq v_m]P\{U \geq v_{m+1}|U \geq v_m, H(v_m), T^*(d) \geq u\}}$$

for $t = 0, \dots, M$, so that $\mathcal{Z}^M(M) = \mathcal{Z}^M$ and

$$\mathcal{Z}^M(0) = \frac{I\{A_1 = d_1(\mathbf{H}_1)\}I(U \geq v_1)}{P\{A_1 = d_1(\mathbf{H}_1)|\mathbf{H}_1\}P\{U \geq v_1|\mathbf{H}_1, A_1, T^*(d) \geq u\}}.$$

Assume that all probabilities in these expressions are positive. Using the SRA and the noninformative censoring assumption

$$\begin{aligned} E\{\mathcal{Z}^M(0)|\mathcal{W}^*, T^*(d) \geq u\} &= E[E\{\mathcal{Z}^M(0)|\mathbf{H}_1, A_1, \mathcal{W}^*, T^*(d) \geq u\}|\mathcal{W}^*, T^*(d) \geq u] \\ &= E\left(\frac{I\{A_1 = d_1(\mathbf{H}_1)\}}{P\{A_1 = d_1(\mathbf{H}_1)|\mathbf{H}_1\}} \right. \\ &\quad \times E\left[\frac{I(U \geq v_1)}{P\{U \geq v_1|\mathbf{H}_1, A_1, T^*(d) \geq u\}} \middle| \mathbf{H}_1, A_1, \mathcal{W}^*, T^*(d) \geq u\right] \middle| \mathcal{W}^*, T^*(d) \geq u\Big) \\ &= E\left[\frac{I\{A_1 = d_1(\mathbf{H}_1)\}}{P\{A_1 = d_1(\mathbf{H}_1)|\mathbf{H}_1\}} \middle| \mathcal{W}^*, T^*(d) \geq u\right] \\ &= E\left(E\left[\frac{I\{A_1 = d_1(\mathbf{H}_1)\}}{P\{A_1 = d_1(\mathbf{H}_1)|\mathbf{H}_1\}} \middle| \mathbf{H}_1, \mathcal{W}^*, T^*(d) \geq u\right] \middle| \mathcal{W}^*, T^*(d) \geq u\right) \\ &= 1 \text{ a.s.} \end{aligned} \quad (\text{A.14})$$

Thus, if we can show that

$$E\{\mathcal{Z}^M(t)|\mathcal{W}^*, T^*(d) \geq u\} = E\{\mathcal{Z}^M(t-1)|\mathcal{W}^*, T^*(d) \geq u\} \text{ a.s.}, \quad (\text{A.15})$$

(A.13) holds by induction.

To show (A.15), note that

$$E\{\mathcal{Z}^M(t)|\mathcal{W}^*, T^*(d) \geq u\} = E[E\{\mathcal{Z}^M(t)|H^-(v_t), U \geq v_t, \mathcal{W}^*, T^*(d) \geq u\}|\mathcal{W}^*, T^*(d) \geq u] \quad \text{a.s.}$$

The inner expectation is equal almost surely to

$$\mathcal{Z}^M(t) = \mathcal{Z}^M(t-1) \left\{ \frac{E(I[A(v_t) = d\{H^-(v_t)\}]I(U \geq v_{t+1})|H^-(v_t), U \geq v_t, \mathcal{W}^*, T^*(d) \geq u)}{P[A(v_t) = d\{H^-(v_t)\}|H^-(v_t), U \geq v_t]P\{U \geq v_{t+1}|U \geq v_t, H(v_t), T^*(d) \geq u\}} \right\}$$

Then using the SRA and the noninformative censoring assumption, by an argument analogous to that in (A.14), the term in large braces is equal to 1 almost surely, and the result follows.

B. More Complex Censoring and Modeling/Estimation of $\omega_k(\mathbf{h}_k, a_k)$

B.1. Dependence of censoring on history

We adopt the assumption of noninformative censoring and further assume that censoring is independent of $H(u)$, or, if dependent on $H(u)$, depends on $H(u)$ only through stage 1 (baseline) treatment assignment. As we note, these assumptions are analogous to those that underlie the standard logrank test for a conventional multi-arm clinical trial.

In some settings, the analyst may believe that censoring, although noninformative as defined here (so depending only on $H(u)$ and not on potential outcomes), depends on $H(u)$ in a more complex fashion. For example, censoring at u may be associated with baseline covariates, covariates that evolve over time, or treatments at stage 2 and higher contained in $H(u)$. The formulation of the general testing procedure outlined in Section 2.2 allows for this possibility. Namely, instead of adopting the simplification (12) of (10) and taking $w(u, d^j) = K_c(u)$, $j = 1, \dots, D$, one can maintain the more general expression for $\Omega(u, d)$ as in (10) and adopt a model for the censoring survival function $K_c\{u|H(u)\}$. The model should be chosen to reflect beliefs about the censoring process; see Tsiatis et al. (2020,

Section 8.3.3, pages 381–382) for discussion of considerations for developing and fitting such models. Specifically, one can adopt an appropriate proportional hazards model and fit the model using the “data” $\{H_i(U_i), U_i, 1 - \Delta_i\}$, $i = 1, \dots, n$, where $H(U_i)$ is the history to U_i for subject i .

Two issues must be addressed under these conditions. One is that account must be taken of the fact that $K_c\{u|H(u)\}$ has been modeled and fitted in obtaining the asymptotic covariance matrix of \mathfrak{T} ; see Section B.2 below. In addition, the weight functions $w(u, d^j)$, $j = 1, \dots, D$, must be specified. One choice is to set these identically equal to 1. A possibly better alternative is to choose these in the spirit of stabilizing weights as in, for example, Tsiatis and Davidian (2022); namely, take $w(u, d^j)$ to be the fitted censoring model evaluated at the averages of components of the history.

Note that, if one believes that censoring does not depend on $H(u)$ or depends on $H(u)$ only through stage 1 treatment, one could estimate $K_c(u)$ (possibly separately by stage 1 treatment as dictated by d^j) using the Kaplan-Meier estimator; however, there is no advantage over the approach we propose, as the weights can be chosen to be equal to the corresponding estimator, in which case $\Omega(u, d^j)$ reduces to (12).

B.2. Modeling and estimation of $\omega_k(\mathbf{h}_k, a_k)$

In Section 2.2, the developments leading to the test statistic $\mathbb{Z} = n^{-1}\mathfrak{T}^T\widehat{\Sigma}^-\mathfrak{T}$ take the probabilities of treatment assignment $\omega_k(\mathbf{h}_k, a_k) = P(A_k = a_k | \mathbf{H}_k = \mathbf{h}_k, \kappa \geq k)$, $k = 1, \dots, K$, to be known functions of \mathbf{h}_k and a_k . Thus, in particular, the form of the asymptotic covariance matrix Σ of \mathfrak{T} and thus the estimator $\widehat{\Sigma}$ is derived under the condition that these probabilities are known, so that the test should achieve the chosen nominal level of significance under H_0 . When the observed data \mathcal{O}_i , $i = 1, \dots, n$, are from a SMART, these probabilities are the randomization probabilities, which of course are known by design. When

the data are from an observational study, these probabilities are unknown; thus, they must be modeled and estimated. As discussed in detail in Section D, estimating these probabilities by fitting an appropriate parametric model and substituting the estimators in (12) of the main paper and thus in \mathfrak{T} will lead to a test that is at least as powerful as that obtained based on known probabilities.

Here, we discuss considerations for modeling and estimating the probabilities $\omega_k(\mathbf{h}_k, a_k)$, $k = 1, \dots, K$. In a SMART, the randomization probabilities $\omega_k(\mathbf{h}_k, a_k)$ can be modeled via an appropriate logistic regression model $\omega_k(\mathbf{h}_k, a_k; \boldsymbol{\gamma}_k)$, say, in terms of a finite-dimensional parameter $\boldsymbol{\gamma}_k$. We consider two examples.

Example 1: Two-stage SMART. Consider the two-stage SMART in Figure 2. Here, $\omega_1(\mathbf{h}_1, a_1) = P(A_1 = a_1 | \mathbf{H}_1 = \mathbf{h}_1, \kappa \geq 1) = P(A_1 = a_1)$ can be represented as

$$\omega_1(\mathbf{h}_1, a_1; \boldsymbol{\gamma}_1) = \left\{ \frac{\exp(\gamma_1)}{1 + \exp(\gamma_1)} \right\}^{I(a_1=1)} \left\{ \frac{1}{1 + \exp(\gamma_1)} \right\}^{I(a_1=0)},$$

which can be fitted by maximum likelihood (ML) using the data A_{1i} , $i = 1, \dots, n$; see below.

It is straightforward that the ML estimator $\hat{\gamma}_1$ is such that $\text{expit}(\hat{\gamma}_1)$ is equal to the sample proportion of subjects randomized at stage 1 to Trt 1, where $\text{expit}(s) = e^s / (1 + e^s)$. At stage 2, letting r_2 be the component/function of \mathbf{h}_2 indicating response status, $\omega_2(\mathbf{h}_2, a_2) = P(A_2 = a_2 | \mathbf{H}_2 = \mathbf{h}_2, \kappa \geq 2)$ can be represented as

$$\begin{aligned} \omega_2(\mathbf{h}_2, a_2; \boldsymbol{\gamma}_2) &= \left\{ \frac{\exp(\gamma_{21})}{1 + \exp(\gamma_{21})} \right\}^{I(a_1=0, r_2=1, a_2=2)} \left\{ \frac{1}{1 + \exp(\gamma_{21})} \right\}^{I(a_1=0, r_2=1, a_2=3)} \\ &\times \left\{ \frac{\exp(\gamma_{22})}{1 + \exp(\gamma_{22})} \right\}^{I(a_1=0, r_2=0, a_2=2)} \left\{ \frac{1}{1 + \exp(\gamma_{22})} \right\}^{I(a_1=0, r_2=0, a_2=4)} \\ &\times \left\{ \frac{\exp(\gamma_{23})}{1 + \exp(\gamma_{23})} \right\}^{I(a_1=1, r_2=1, a_2=2)} \left\{ \frac{1}{1 + \exp(\gamma_{23})} \right\}^{I(a_1=1, r_2=1, a_2=5)} \\ &\times \left\{ \frac{\exp(\gamma_{24})}{1 + \exp(\gamma_{24})} \right\}^{I(a_1=1, r_2=0, a_2=3)} \left\{ \frac{1}{1 + \exp(\gamma_{24})} \right\}^{I(a_1=1, r_2=0, a_2=5)}. \end{aligned}$$

This model can be fitted by ML to the data $\{\mathbf{H}_{2i}, A_{2i}\}$ for all i for whom $\kappa_i = 2$ (see below).

The ML estimator $\hat{\boldsymbol{\gamma}}_2 = (\hat{\gamma}_{21}, \hat{\gamma}_{22}, \hat{\gamma}_{23}, \hat{\gamma}_{24})^T$ is such that, for example, $\text{expit}(\hat{\gamma}_{21})$ is equal to

the sample proportion of subjects who were randomized at stage 1 to Trt 0, reached stage 2 without experiencing the event or censoring, responded to Trt 0, and were randomized to Trt 2.

The ML estimator for $\boldsymbol{\gamma} = (\gamma_1, \boldsymbol{\gamma}_2^T)^T$ is found by maximizing the loglikelihood for $\boldsymbol{\gamma}$; the likelihood contribution for a single subject is given by

$$\begin{aligned} & \frac{\exp\{\gamma_1 I(A_1 = 1)\}}{1 + \exp(\gamma_1)} \\ & \times \left(\left[\frac{\exp\{\gamma_{21} I(A_2 = 2)\}}{1 + \exp(\gamma_{21})} \right]^{I(A_1=0, R_2=1)} \left[\frac{\exp\{\gamma_{22} I(A_2 = 2)\}}{1 + \exp(\gamma_{22})} \right]^{I(A_1=0, R_2=0)} \right. \\ & \times \left. \left[\frac{\exp\{\gamma_{23} I(A_2 = 2)\}}{1 + \exp(\gamma_{23})} \right]^{I(A_1=1, R_2=1)} \left[\frac{\exp\{\gamma_{24} I(A_2 = 3)\}}{1 + \exp(\gamma_{24})} \right]^{I(A_1=1, R_2=0)} \right)^{I(\kappa=2)}. \end{aligned} \quad (\text{B.1})$$

It is straightforward that the associated score vector is

$$\mathbf{S}_{\boldsymbol{\gamma}}(\boldsymbol{\gamma}) = \begin{pmatrix} \{I(A_1 = 1) - \text{expit}(\gamma_1)\} \\ I(A_1 = 0, R_2 = 1, \kappa = 2) \{I(A_2 = 2) - \text{expit}(\gamma_{21})\} \\ I(A_1 = 0, R_2 = 0, \kappa = 2) \{I(A_2 = 2) - \text{expit}(\gamma_{22})\} \\ I(A_1 = 1, R_2 = 1, \kappa = 2) \{I(A_2 = 2) - \text{expit}(\gamma_{23})\} \\ I(A_1 = 1, R_2 = 0, \kappa = 2) \{I(A_2 = 3) - \text{expit}(\gamma_{24})\} \end{pmatrix} \quad (\text{B.2})$$

Example 2: Observational study with two decision points. When the data are from an observational study, the analyst must posit models $\omega_k(\mathbf{h}_k, a_k; \boldsymbol{\gamma}_k)$, $k = 1, \dots, K$, that incorporate possible dependence of the probabilities of treatment on past history both to acknowledge the likely dependence of treatment assignment on history and to account for possible confounding. Consider a setting with $K = 2$ stages where subjects were observed to receive one of two treatments, coded as 0 and 1, at stage 1, and, among those who reached stage 2 without having experienced the event or censoring, responders continued on stage 1 treatment and nonresponders were observed to receive one of two treatments, also coded as 0 and 1 (but not necessarily the same as those at stage 1). Typical logistic regression models are of the

form

$$\begin{aligned}\omega_1(\mathbf{h}_1, a_1; \gamma_1) &= \left\{ \frac{\exp(\gamma_1^T \tilde{\mathbf{h}}_1)}{1 + \exp(\gamma_1^T \tilde{\mathbf{h}}_1)} \right\}^{I(a_1=1)} \left\{ \frac{1}{1 + \exp(\gamma_1^T \tilde{\mathbf{h}}_1)} \right\}^{I(a_1=0)}, \\ \omega_2(\mathbf{h}_2, a_2; \gamma_2) &= \left\{ \frac{\exp(\gamma_{21}^T \tilde{\mathbf{h}}_2)}{1 + \exp(\gamma_{21}^T \tilde{\mathbf{h}}_2)} \right\}^{I(a_1=0, r_2=0, a_2=1)} \left\{ \frac{1}{1 + \exp(\gamma_{21}^T \tilde{\mathbf{h}}_2)} \right\}^{I(a_1=0, r_2=0, a_2=0)} \\ &\quad \times \left\{ \frac{\exp(\gamma_{22}^T \tilde{\mathbf{h}}_2)}{1 + \exp(\gamma_{22}^T \tilde{\mathbf{h}}_2)} \right\}^{I(a_1=1, r_2=0, a_2=1)} \left\{ \frac{1}{1 + \exp(\gamma_{22}^T \tilde{\mathbf{h}}_2)} \right\}^{I(a_1=1, r_2=0, a_2=0)},\end{aligned}$$

where $\tilde{\mathbf{h}}_k$ is a vector of functions of elements of \mathbf{h}_k , ordinarily with a “1” in the first position to yield an “intercept” term, $k = 1, 2$, so could include, for example, interactions, polynomial terms or splines, and so on. Analogous to (B.1), the contribution of a single subject to the likelihood for $\gamma = (\gamma_1^T, \gamma_2^T)^T$ is given by

$$\begin{aligned}& \frac{\exp\{\gamma_1^T \tilde{\mathbf{H}}_1 I(A_1 = 1)\}}{1 + \exp(\gamma_1^T \tilde{\mathbf{H}}_1)} \left[\frac{\exp\{\gamma_{21}^T \tilde{\mathbf{H}}_2 I(A_2 = 1)\}}{1 + \exp(\gamma_{21}^T \tilde{\mathbf{H}}_2)} \right]^{I(A_1=0, R_2=0, \kappa=2)} \\ & \times \left[\frac{\exp\{\gamma_{22}^T \tilde{\mathbf{H}}_2 I(A_2 = 1)\}}{1 + \exp(\gamma_{22}^T \tilde{\mathbf{H}}_2)} \right]^{I(A_1=1, R_2=0, \kappa=2)},\end{aligned}\tag{B.3}$$

and the ML estimator for γ maximizes in γ the corresponding loglikelihood. The associated score vector is

$$\mathbf{S}_\gamma(\gamma) = \begin{pmatrix} \{I(A_1 = 1) - \text{expit}(\gamma_1^T \tilde{\mathbf{H}}_1)\} \tilde{\mathbf{H}}_1 \\ I(A_1 = 0, R_2 = 0, \kappa = 2) \{I(A_2 = 1) - \text{expit}(\gamma_{21}^T \tilde{\mathbf{H}}_2)\} \tilde{\mathbf{H}}_2 \\ (A_1 = 1, R_2 = 0, \kappa = 2) \{I(A_2 = 1) - \text{expit}(\gamma_{22}^T \tilde{\mathbf{H}}_2)\} \tilde{\mathbf{H}}_2 \end{pmatrix}.\tag{B.4}$$

C. Representation of \mathfrak{T} as a Sum of iid Terms

We wish to show that $n^{-1/2} \times (11)$,

$$n^{-1/2} \mathfrak{T}^j = n^{-1/2} \sum_{i=1}^n \int_0^\infty \Omega_i(u, d^j) \{dN_i(u) - d\hat{\Lambda}_0(u) Y_i(u)\},$$

for each $j = 1, \dots, D - 1$, satisfies (13). We begin by adding and subtracting $d\Lambda_0(u)$ in the integral, to obtain

$$\begin{aligned} n^{-1/2} \sum_{i=1}^n \int_0^\infty \Omega_i(u, d^j) [dN_i(u) - \{d\hat{\Lambda}_0(u) + d\Lambda_0(u) - d\Lambda_0(u)\} Y_i(u)] \\ = n^{-1/2} \sum_{i=1}^n \int_0^\infty \Omega_i(u, d^j) \{dN_i(u) - d\Lambda_0(u) Y_i(u)\} \\ - n^{-1/2} \sum_{i=1}^n \int_0^\infty \Omega_i(u, d^j) \{d\hat{\Lambda}_0(u) - d\Lambda_0(u)\} Y_i(u). \end{aligned} \quad (\text{C.1})$$

Defining $d\bar{N}_i(u) = \sum_{j=1}^D \Omega_i(u, d^j) dN_i(u)$, $\bar{Y}_i(u) = \sum_{j=1}^D \Omega_i(u, d^j) Y_i(u)$, and

$$\hat{q}(u, d) = \{n^{-1} \sum_{i=1}^n \Omega_i(u, d) Y_i(u)\} / \{n^{-1} \sum_{i=1}^n \bar{Y}_i(u)\},$$

so that

$$d\hat{\Lambda}_0(u) = \{n^{-1} \sum_{i=1}^n d\bar{N}_i(u)\} / \{n^{-1} \sum_{i=1}^n \bar{Y}_i(u)\},$$

substituting this expression in (C.1) and rearranging and using the definition of $\hat{q}(u, d^j) = \{n^{-1} \sum_{i=1}^n \Omega_i(u, d^j) Y_i(u)\} / \{n^{-1} \sum_{i=1}^n \bar{Y}_i(u)\}$, (C.1) becomes

$$\begin{aligned} n^{-1/2} \sum_{i=1}^n \int_0^\infty \hat{q}(u, d^j) \{d\bar{N}_i(u) - d\Lambda_0(u) \bar{Y}_i(u)\} \\ = n^{-1/2} \sum_{i=1}^n \int_0^\infty \hat{q}(u, d^j) \left\{ \sum_{j'=1}^D \Omega_i(u, d^{j'}) dN_i(u) - d\Lambda_0(u) \sum_{j'=1}^D \Omega_i(u, d^{j'}) Y_i(u) \right\} \\ = n^{-1/2} \sum_{i=1}^n \sum_{j'=1}^D \int_0^\infty \Omega_i(u, d^{j'}) \hat{q}(u, d^j) \{dN_i(u) - d\Lambda_0(u) Y_i(u)\}. \end{aligned} \quad (\text{C.2})$$

Thus, using (C.2), we have

$$\begin{aligned} n^{-1/2} \mathfrak{T}^j = n^{-1/2} \sum_{i=1}^n \left[\int_0^\infty \Omega_i(u, d^j) \{dN_i(u) - d\Lambda_0(u) Y_i(u)\} \right. \\ \left. - \sum_{j'=1}^D \int_0^\infty \Omega_i(u, d^{j'}) \hat{q}(u, d^j) \{dN_i(u) - d\Lambda_0(u) Y_i(u)\} \right]. \end{aligned} \quad (\text{C.3})$$

For $j = 1, \dots, D - 1$, under the consistency assumption, $\hat{q}(u, d^j)$ converges in probability as $n \rightarrow \infty$ to $q(u, d^j) = E\{\Omega(u, d^j) Y^*(u, d^j)\} / \sum_{j'=1}^D E\{\Omega(u, d^{j'}) Y^*(u, d^{j'})\}$. Then under

regularity conditions, $n^{-1/2}$ times (C.3) satisfies

$$\begin{aligned} n^{-1/2} \sum_{i=1}^n \left[\sum_{j'=1}^D \int_0^\infty \Omega_i(u, d^{j'}) \widehat{q}(u, d^j) \{dN_i(u) - d\Lambda_0(u)Y_i(u)\} \right] \\ = n^{-1/2} \sum_{i=1}^n \left[\sum_{j'=1}^D \int_0^\infty \Omega_i(u, d^{j'}) q(u, d^j) \{dN_i(u) - d\Lambda_0(u)Y_i(u)\} \right] + o_p(1), \end{aligned}$$

leading to (13); namely,

$$\begin{aligned} n^{-1/2} \mathfrak{T}^j &= n^{-1/2} \sum_{i=1}^n \left[\int_0^\infty \Omega_i(u, d^j) \{dN_i(u) - d\Lambda_0(u)Y_i(u)\} \right. \\ &\quad \left. - \sum_{j'=1}^D \int_0^\infty \Omega_i(u, d^{j'}) q(u, d^j) \{dN_i(u) - d\Lambda_0(u)Y_i(u)\} \right] + o_p(1), \\ &= n^{-1/2} \sum_{i=1}^n \mathfrak{T}_i^j + o_p(1), \end{aligned}$$

which shows that $n^{-1/2} \mathfrak{T}^j$ in (11) is asymptotically equivalent to $n^{-1/2}$ times a sum of iid terms, and thus so is $n^{-1/2} \mathfrak{T} = n^{-1/2} (\mathfrak{T}^1, \dots, \mathfrak{T}^{D-1})^T$. Accordingly, if we define $\mathfrak{T}_i = (\mathfrak{T}_i^1, \dots, \mathfrak{T}_i^{D-1})^T$, which are iid for $i = 1, \dots, n$, so that $n^{-1/2} \mathfrak{T} = n^{-1/2} \sum_{i=1}^n \mathfrak{T}_i + o_p(1)$, it follows by standard asymptotic normal theory that the asymptotic covariance matrix of $n^{-1/2} \mathfrak{T}$ can be approximated by $\Sigma = n^{-1} \sum_{i=1}^n (\mathfrak{T}_i \mathfrak{T}_i^T)$. Because $q(u, d^j)$ and $d\Lambda_0(u)$ are not known, it is natural to substitute $\widehat{q}(u, d^j)$ for $q(u, d^j)$ and $d\widehat{\Lambda}_0(u)$ for $d\Lambda_0(u)$ to obtain $\widehat{\mathfrak{T}}_i^j$ and $\widehat{\mathfrak{T}}_i = (\widehat{\mathfrak{T}}_i^1, \dots, \widehat{\mathfrak{T}}_i^{D-1})^T$, say, and estimate Σ by $\widehat{\Sigma} = n^{-1} \sum_{i=1}^n (\widehat{\mathfrak{T}}_i \widehat{\mathfrak{T}}_i^T)$. In fact, it is straightforward to observe that $n^{-1/2} \mathfrak{T} = n^{-1/2} \widehat{\mathfrak{T}} = n^{-1/2} \sum_{i=1}^n \widehat{\mathfrak{T}}_i$, so the test statistic can be formed equivalently as $\mathbb{Z} = n^{-1} \widehat{\mathfrak{T}}^T \widehat{\Sigma}^{-1} \widehat{\mathfrak{T}}$.

D. Improving Efficiency

D.1. Increased efficiency using estimated randomization probabilities

In Section B, we discuss modeling and estimation (by ML) of the probabilities $\omega_k(\mathbf{h}_k, a_k)$, $k = 1, \dots, K$. Assuming that suitable models $\omega_k(\mathbf{h}_k, a_k; \boldsymbol{\gamma}_k)$, $k = 1, \dots, K$, have been posited following the considerations in Section B and that $\boldsymbol{\gamma} = (\boldsymbol{\gamma}_1^T, \dots, \boldsymbol{\gamma}_K^T)^T$ is estimated via ML, we now discuss the implications of substituting estimated probabilities obtained from the

fitted models for the known probabilities in (12) and thus in \mathfrak{T} in forming the test statistic. Namely, we argue that substituting estimated probabilities for known probabilities yields a more powerful test as long as the models are correctly specified, and we demonstrate that estimation of γ must be taken into appropriate account in deriving and estimating the asymptotic covariance matrix of \mathfrak{T} with which to form the test statistic. Thus, with data from a SMART, it is advantageous to estimate the known randomization probabilities and use the test statistic with this appropriate covariance matrix. In fact, the arguments show that, if there are components of the histories \mathbf{H}_k that are associated with the outcome, it is possible to exploit these associations to gain further efficiency and thus further increases in power, analogous to the familiar tactic of covariate adjustment.

Denote \mathfrak{T} with elements as in (11) with the models $\omega_k(\mathbf{h}_k, a_k; \gamma_k)$, $k = 1, \dots, K$ substituted as $\mathfrak{T}(\gamma)$, and, as in Section B, let $\hat{\gamma}$ be the ML estimator for γ . According to Theorem 9.1 of Tsiatis (2006), with correctly-specified models, substituting $\hat{\gamma}$ in these models is equivalent to projecting each of the $D - 1$ components of \mathfrak{T} , which contain the known probabilities, onto the space spanned by the score vector associated with the likelihood under the models. Because $\mathfrak{T}(\hat{\gamma})$ involves a projection, the asymptotic covariance matrix of $\mathfrak{T}(\hat{\gamma})$ is no larger than that of \mathfrak{T} with the known probabilities in the sense of nonnegative definiteness, which implies that estimating γ results in efficiency gains relative to using the known probabilities. Thus, a modified test statistic, $\mathbb{Z}(\hat{\gamma})$, say, that takes these features into account will yield a more powerful test than the test statistic \mathbb{Z} using the known probabilities.

Letting Σ_γ be the asymptotic covariance matrix of $\mathfrak{T}(\hat{\gamma})$, we now present a heuristic argument to motivate our proposed approach to obtaining an estimator for Σ , $\hat{\Sigma}_\gamma$, to be used to form the test statistic. We first provide a representation of the score vector associated with the ML estimator $\hat{\gamma}$ in generic models $\omega_k(\mathbf{h}_k, a_k; \gamma_k)$, $k = 1, \dots, K$; examples of score vectors in the specific models considered in Section B are in (B.2) and (B.4). Similar to

the formulation in Section A, let $A(u)$ denote the treatment received at time $u \geq 0$; and let M denote the number of all possible treatment options that could be administered at u , including “do nothing” if u is not the time of a decision point. Let $H^-(u)$ denote the history of information at time u but not including the treatment received at time u . Let $\omega\{\ell, u, H^-(u)\} = P\{A(u) = \ell | H^-(u)\}$, the probability of being assigned treatment ℓ at time u given the history $H^-(u)$, $\ell = 1, \dots, M$, where this probability is positive only for treatments ℓ that are feasible at time u given the history $H^-(u)$.

Consider a model for $\omega\{\ell, u, H^-(u)\}$ given by $\omega\{\ell, u, H^-(u); \gamma\}$ indexed by the finite-dimensional parameter γ . Then the contribution to the likelihood for γ for an individual, under the assumptions of consistency, the SRA, and positivity, is given by

$$\prod_{u \leq U} \prod_{\ell=1}^M \omega\{\ell, u, H^-(u); \gamma\}^{I\{A(u)=\ell\}},$$

so that the contribution to the loglikelihood is

$$\int_0^U \sum_{\ell=1}^M I\{A(u) = \ell\} \log [\omega\{\ell, u, H^-(u); \gamma\}].$$

Then the score vector is the first partial derivative of this expression, namely,

$$\mathbf{S}_\gamma(\gamma) = \int_0^U \sum_{\ell=1}^M I\{A(u) = \ell\} \frac{\partial / \partial \gamma [\omega\{\ell, u, H^-(u); \gamma\}]}{\omega\{\ell, u, H^-(u); \gamma\}}.$$

Because $\sum_{\ell=1}^M \omega\{\ell, u, H^-(u); \gamma\} = 1$ for all γ ,

$$\sum_{\ell=1}^M \partial / \partial \gamma [\omega\{\ell, u, H^-(u); \gamma\}] = 0,$$

so that

$$\mathbf{S}_\gamma(\gamma) = \int_0^U \sum_{\ell=1}^M [I\{A(u) = \ell\} - \omega\{\ell, u, H^-(u); \gamma\}] \frac{\partial / \partial \gamma [\omega\{\ell, u, H^-(u); \gamma\}]}{\omega\{\ell, u, H^-(u); \gamma\}}. \quad (\text{D.1})$$

Aligned with Tsiatis (2006, Theorem 9.1), consider the space of “augmentation terms,” denoted by Λ_2 , defined as all functions of the observed data, $g(\mathcal{O})$, say, such that

$$E\{g(\mathcal{O}) | \mathcal{W}^*\} = 0.$$

Motivated by the space spanned by score vectors with respect to γ (D.1), define the subspace

Λ_{Aug} of Λ_2 by the space of functions of the form

$$\int_0^U \sum_{\ell=1}^M [I\{A(u) = \ell\} - \omega\{\ell, u, H^-(u); \gamma_0\}] b_\ell\{u, H^-(u)\}, \quad (\text{D.2})$$

where γ_0 is the true value of γ so that $\omega\{\ell, u, H^-(u); \gamma_0\} =$ the true $\omega\{\ell, u, H^-(u)\}$; and $b_\ell\{u, H^-(u)\}$ are arbitrary functions. That any element of Λ_{Aug} is contained in Λ_2 follows because

$$\begin{aligned} & E\left([I\{A(u) = \ell\} - \omega\{\ell, u, H^-(u); \gamma_0\}] b_\ell\{u, H^-(u)\} | \mathcal{W}^*\right) \\ &= E\left\{E\left([I\{A(u) = \ell\} - \omega\{\ell, u, H^-(u); \gamma_0\}] b_\ell\{u, H^-(u)\} | H^-(u), \mathcal{W}^*\right) \middle| \mathcal{W}^*\right\} \\ &= 0, \end{aligned}$$

using the fact that $E\left([I\{A(u) = \ell\} | H^-(u), \mathcal{W}^*\right) = \omega\{\ell, u, H^-(u); \gamma_0\}$. Clearly, from (D.1), the space Λ_{Aug} contains the space spanned by $\mathbf{S}_\gamma(\gamma)$. Thus, by considering test statistics formed by projecting each of the $D - 1$ components of \mathfrak{T} onto the space Λ_{Aug} , we can obtain tests that are more powerful than those based on \mathbb{Z} using known probabilities. These developments suggest the approach presented here for constructing the test statistic. Namely, instead of considering the entire space Λ_{Aug} , we consider projecting onto a subspace spanned by a finite number of elements of Λ_{Aug} , which are of the form in (D.2) with the elements of Λ_{Aug} determined by analyst-specified choices for the functions of the history $b_\ell\{u, H^-(u)\}$; refer to these functions as basis functions. As long as this subspace contains all the elements of $\mathbf{S}_\gamma(\gamma)$, so that the chosen basis functions include the components of $\mathbf{S}_\gamma(\gamma)$, the efficiency gain associated with estimation of γ will be taken into account.

Based on these results, operationally, to obtain $\widehat{\Sigma}_\gamma$ with which to form a test statistic, for each $j = 1, \dots, D$, proceed as follows. Denote by $\widehat{\mathfrak{T}}_i^j(\widehat{\gamma})$ $\widehat{\mathfrak{T}}_i^j$ (i.e., as in (13) with $\widehat{q}(u, d^j)$ and $d\widehat{\Lambda}_0(u)$ substituted) for subject i , $i = 1, \dots, n$, with the estimated probabilities substituted. Denote by $\mathbf{S}_{\gamma,i}(\widehat{\gamma})$ the score vector associated with the likelihood for γ for subject i in the chosen models $\omega_k(\mathbf{h}_k, a_k; \gamma_k)$, $k = 1, \dots, K$, with the estimated probabilities substituted. Then for each j carry out a linear regression of the $\widehat{\mathfrak{T}}_i^j(\widehat{\gamma})$ on $\mathbf{S}_{\gamma,i}(\widehat{\gamma})$ and form for each

subject $i = 1, \dots, n$ the residuals from this fit, $\widehat{\mathfrak{T}}_i^{j,R}(\widehat{\gamma})$, say. Then, defining $\widehat{\mathfrak{T}}_i^R(\widehat{\gamma}) = \{\widehat{\mathfrak{T}}_i^{1,R}(\widehat{\gamma}), \dots, \widehat{\mathfrak{T}}_i^{D-1,R}(\widehat{\gamma})\}^T$, define

$$\widehat{\Sigma}_\gamma = n^{-1} \sum_{i=1}^n \{\widehat{\mathfrak{T}}_i^R(\widehat{\gamma}) \widehat{\mathfrak{T}}_i^R(\widehat{\gamma})^T\}. \quad (\text{D.3})$$

Letting $\widehat{\mathfrak{T}}^R(\widehat{\gamma}) = \sum_{i=1}^n \widehat{\mathfrak{T}}_i^R(\widehat{\gamma})$, form the test statistic as

$$\mathbb{Z}(\widehat{\gamma}) = n^{-1} \widehat{\mathfrak{T}}^R(\widehat{\gamma})^T \widehat{\Sigma}_\gamma^{-1} \widehat{\mathfrak{T}}^R(\widehat{\gamma}) \quad (\text{D.4})$$

As a demonstration, consider Example 1 in Section B of a two-stage SMART. Here, the randomization probabilities are known, but the foregoing discussion indicates that a more powerful test can be obtained by estimating the randomization probabilities using sample proportions. In this case, to obtain the test statistic, for each $j = 1, \dots, 8$, perform a linear regression with dependent variable $\widehat{\mathfrak{T}}_i^j(\widehat{\gamma})$ and design matrix with i th row, from (B.2),

$$\begin{aligned} & [\{I(A_{1i} = 1) - \text{expit}(\widehat{\gamma}_1)\}, I(A_{1i} = 0, R_{2i} = 1, \kappa_i = 2)\{I(A_{2i} = 2) - \text{expit}(\widehat{\gamma}_{21})\}, \\ & I(A_{1i} = 0, R_{2i} = 0, \kappa_i = 2)\{I(A_{2i} = 2) - \text{expit}(\widehat{\gamma}_{22})\}, \\ & I(A_{1i} = 1, R_{2i} = 1, \kappa_i = 2)\{I(A_{2i} = 2) - \text{expit}(\widehat{\gamma}_{23})\}, \\ & I(A_{1i} = 1, R_{2i} = 0, \kappa_i = 2)\{I(A_{2i} = 3) - \text{expit}(\widehat{\gamma}_{24})\}], \end{aligned} \quad (\text{D.5})$$

and obtain the residuals $\widehat{\mathfrak{T}}_i^{j,R}(\widehat{\gamma})$ from this fit and then $\widehat{\Sigma}_\gamma$ as in (D.3) and the test statistic as in (D.4).

Similarly, in Example 2 in Section B of a two-stage observational study, where of necessity $\omega_k(\mathbf{h}_k, a_k)$, $k = 1, 2$, must be modeled and fitted, the test statistic would be found by, for each $j = 1, \dots, 4$, by linear regression with dependent variable $\widehat{\mathfrak{T}}_i^j(\widehat{\gamma})$ and design matrix with i th row, from (B.4),

$$\begin{aligned} & [\{I(A_{1i} = 1) - \text{expit}(\widehat{\gamma}_1^T \widetilde{\mathbf{H}}_{1i})\} \widetilde{\mathbf{H}}_{1i}^T, I(A_{1i} = 0, R_{2i} = 0, \kappa_i = 2)\{I(A_{2i} = 1) - \text{expit}(\widehat{\gamma}_{21}^T \widetilde{\mathbf{H}}_{2i})\} \widetilde{\mathbf{H}}_{2i}^T, \\ & I(A_{1i} = 1, R_{2i} = 0, \kappa_i = 2)\{I(A_{2i} = 1) - \text{expit}(\widehat{\gamma}_{22}^T \widetilde{\mathbf{H}}_{2i})\} \widetilde{\mathbf{H}}_{2i}^T]. \end{aligned}$$

Then obtain the residuals $\widehat{\mathfrak{T}}_i^{j,R}(\widehat{\gamma})$ from this regression and proceed as above.

D.2. Remarks on Li et al. (2014)

It is straightforward to demonstrate that the approach of Li et al. (2014) can be viewed as a special case of our general testing approach, although formulated explicitly and evaluated in their article only for a situation analogous to that of Example 2 in Section B. Thus, the foregoing developments contradict the claim of Li et al. (2014) that “estimation of these (treatment selection) probabilities does not have an effect on the asymptotic distribution of the weighted logrank statistic.” In this example and in general, the above arguments demonstrate that there is an effect of estimation of the probabilities (i.e., estimation of γ here). The proof of Theorem 1 in the Appendix of Li et al. (2014) that there is no effect of estimating the probabilities hinges on the equality in their equation (5). If (5) is true, it implies that their quantity A_n in their equation (2) converges in probability to zero and thus that there is no dependence of the large-sample distribution of the quantity on the left hand side of their (2) and thus their test statistic on estimation of their parameter θ (γ here). However, we now argue that the equality in (5) does not hold; we provide a heuristic sketch of the argument. Using roughly their notation and letting Z denote the data, the expectation on the left hand side of their equation (5) is of the form

$$E_{\theta} \left[\frac{\partial}{\partial \theta} \{W(Z; \theta)\} \left\{ \int_0^{\tau} \xi(u) dM(u) \right\} \right], \quad (\text{D.6})$$

where $W(Z; \theta)$ and $dM(u)$ are functions of Z and $\xi(u)$ is a deterministic function, and E_{θ} indicates expectation with respect to the distribution of the data evaluated at θ . The distribution of the data depends on θ , as the data involve treatment assignment indicators, so that, letting $p(z; \theta)$ denote the density of Z , (D.6) is

$$\int \frac{\partial}{\partial \theta} \{W(z; \theta)\} \left\{ \int_0^{\tau} \xi(u) dM(u) \right\} p(z; \theta) dz. \quad (\text{D.7})$$

However, the right hand side of their (5) is, interchanging expectation and integration,

$$\begin{aligned} \frac{\partial}{\partial \theta} E_{\theta} \left[W(Z; \theta) \left\{ \int_0^{\tau} \xi(u) dM(u) \right\} \right] &= \frac{\partial}{\partial \theta} \left[\int W(z; \theta) \left\{ \int_0^{\tau} \xi(u) dM(u) \right\} p(z; \theta) dz \right] \\ &= \int \frac{\partial}{\partial \theta} \{W(z; \theta)\} \left\{ \int_0^{\tau} \xi(u) dM(u) \right\} p(z; \theta) dz + \int W(z; \theta) \left\{ \int_0^{\tau} \xi(u) dM(u) \right\} S_{\theta}(z; \theta) p(z; \theta) dz, \end{aligned} \quad (\text{D.8})$$

where $S_{\theta}(z; \theta) = \partial/\partial \theta \{p(z; \theta)\}/p(z; \theta)$ is the score associated with ML estimation of θ .

Accordingly, their equation (5) does not hold as shown; rather, from (D.7) and (D.8),

$$\begin{aligned} E_{\theta} \left[\frac{\partial}{\partial \theta} \{W(Z; \theta)\} \left\{ \int_0^{\tau} \xi(u) dM(u) \right\} \right] \\ = \frac{\partial}{\partial \theta} E_{\theta} \left[W(Z; \theta) \left\{ \int_0^{\tau} \xi(u) dM(u) \right\} \right] - E_{\theta} \left[W(z; \theta) \left\{ \int_0^{\tau} \xi(u) dM(u) \right\} S_{\theta}(z; \theta) \right]. \end{aligned} \quad (\text{D.9})$$

Equation (4) of Li et al. (2014) implies that the first term in (D.9) is equal to zero; thus, their equation (5) should be

$$E_{\theta} \left[\frac{\partial}{\partial \theta} \{W(Z; \theta)\} \left\{ \int_0^{\tau} \xi(u) dM(u) \right\} \right] = -E_{\theta} \left[W(z; \theta) \left\{ \int_0^{\tau} \xi(u) dM(u) \right\} S_{\theta}(z; \theta) \right] \neq 0,$$

so that A_n in their (2) converges in probability to the right hand side of this expression rather than to zero. The implication is that there is in fact an effect of estimation of their parameter θ indexing the models for the treatment probabilities (our γ), which depends on the score vector, analogous to our results.

In fact, because as above estimation of γ leads to an increase in efficiency and because Li et al. (2014) do not take into account the effect of estimating γ in the covariance matrix used to form their test statistic, the covariance matrix they use overstates the uncertainty in the components of \mathfrak{T} . Consequently, under H_0 , their proposed test is expected to be conservative under H_0 . This behavior is evident in their Table 1, which shows that, even with sample sizes as large as $n = 10,000$, the empirical type I error rate is lower than the nominal 0.05 level of significance.

D.3. Gaining additional efficiency using covariates

Returning to our approach, the above arguments and form of the space Λ_{Aug} suggest that, if there are components of the history at any decision point that are associated with the outcome, it may be possible to gain further efficiency by exploiting these associations. In particular, consider a SMART. In addition to including as basis functions the elements of the score vector associated with estimators of the randomization probabilities as above, one can also include additional basis functions that are functions of these components of the history. For example, in the SMART in Example 1, in addition to having columns that are determined by elements of (B.2) for each subject i as in (D.5), one could add further columns to the design matrix by appending to the i th row the additional components

$$\begin{aligned} & \left[\{I(A_{1i} = 1) - \text{expit}(\hat{\gamma}_1)\} \widetilde{\mathbf{H}}_{1i}^T, I(A_{1i} = 0, R_{2i} = 1, \kappa_i = 2) \{I(A_{2i} = 2) - \text{expit}(\hat{\gamma}_{21})\} \widetilde{\mathbf{H}}_{21i,i}^T, \right. \\ & \quad I(A_{1i} = 0, R_{2i} = 0, \kappa_i = 2) \{I(A_{2i} = 2) - \text{expit}(\hat{\gamma}_{22})\} \widetilde{\mathbf{H}}_{22,i}^T, \\ & \quad I(A_{1i} = 1, R_{2i} = 1, \kappa_i = 2) \{I(A_{2i} = 2) - \text{expit}(\hat{\gamma}_{23})\} \widetilde{\mathbf{H}}_{23,i}^T, \\ & \quad \left. I(A_{1i} = 1, R_{2i} = 0, \kappa_i = 2) \{I(A_{2i} = 3) - \text{expit}(\hat{\gamma}_{24})\} \widetilde{\mathbf{H}}_{24,i}^T \right], \end{aligned} \quad (\text{D.10})$$

where now $\widetilde{\mathbf{H}}_1$ and $\widetilde{\mathbf{H}}_{2\ell}$, $\ell = 1, \dots, 4$, are vectors of basis functions of \mathbf{H}_1 and \mathbf{H}_2 , but with no “1” in the first position. For example, if \mathbf{H}_1 contains two baseline covariates X_{11}, X_{12} , and \mathbf{H}_2 contains one covariate X_2 ascertained between Decisions 1 and 2, one could take $\widetilde{\mathbf{H}}_1 = (X_{11}, X_{12})^T$ and $\widetilde{\mathbf{H}}_{2\ell} = (X_{11}, X_{12}, X_2)^T$, $\ell = 1, \dots, 4$. In this case, the design matrix would be of dimension $(n \times 19)$. Of course, the analyst must be judicious in specifying these vectors of basis functions, as including in them information in the history for which the association is not strong could lead to finite-sample “noise” that diminishes or offsets efficiency gains in finite samples. To obtain the test statistic, one would proceed as above and obtain the residuals $\widehat{\mathfrak{T}}_i^{j,R}(\hat{\gamma})$ from the regression using this design matrix, compute $\widehat{\Sigma}_{\gamma}$ as in (D.3), and form the test statistic as in (D.4).

D.4. Remarks on Kidwell and Wahed (2013)

We provide an argument demonstrating the contention of Section 2.4 that the components of the vector need not be martingales with respect to the filtration given by Kidwell and Wahed (2013). Because the test of Kidwell and Wahed (2013) is applicable for $K = 2$ and the design in Figure 3 without the control regime, and their formulation does not involve covariates, we consider this setting with no available covariate information for simplicity. In this case, the history up to time $u \geq 0$ is given by (recall $\mathcal{T}_1 = 0$ is superfluous, so we eliminate it from the history for the purpose of this argument)

$$H(u) = \{A_1, I(\kappa \geq 2, \mathcal{T}_2 \leq u), I(\kappa \geq 2, \mathcal{T}_2 \leq u)(\mathcal{T}_2, A_2), I(U < u), (U, \Delta)I(U < u)\}$$

is the filtration of Kidwell and Wahed (2013) in the current notation.

Under the null hypothesis H_0 in (1), the hazard rates $\lambda(u, d^j)$, $j = 1, \dots, D = 4$ are all equal to the common hazard rate $\lambda_0(u)$. In computing the covariance matrix of the numerator of their test statistic under H_0 , Kidwell and Wahed (2013) invoke the theory of counting process martingales. Specifically, the authors assume that the increment $dM(u) = dN(u) - d\Lambda_0(u)Y(u)$, where $N(u) = I(U \leq u, \Delta = 1)$ and $Y(u) = I(U \geq u)$, is a $H(u^-)$ martingale increment; i.e.,

$$E\{dM(u) \mid H(u^-)\} = 0.$$

Consequently, for each regime j ,

$$E\{\Omega(u, d^j)dM(u) \mid H(u^-)\} = \Omega(u, d^j)E\{dM(u) \mid H(u^-)\} = 0.$$

However, in general, the intensity process for the counting process $N(u)$ is

$$\begin{aligned} E\{dN(u) \mid H(u^-)\} &= [d\Lambda_{NR}(u, A_1)\{1 - I(\kappa \geq 2, \mathcal{T}_2 \leq u)\} \\ &\quad + d\Lambda_R(u, A_1, \mathcal{T}_2, A_2)I(\kappa \geq 2, \mathcal{T}_2 \leq u)]Y(t). \end{aligned}$$

Here, $d\Lambda_{NR}(u, A_1)$ is the hazard of experiencing the event at time u for an individual who is at risk at time u and has not yet had a response, which may be a function of u and A_1 ; and

$d\Lambda_R(u, A_1, \mathcal{T}_2, A_2)$ is the hazard of experiencing the event at time u for an individual who is at risk at time u , has achieved a response at time $\mathcal{T}_2 < u$, and received treatments A_1 and A_2 at Decisions 1 and 2, which may be a function of u , A_1 , \mathcal{T}_2 , and A_2 .

In the data generative scenarios of Kidwell and Wahed (2013) (our Scenarios 1 and 2, for example) and our Scenarios 3-5, under the null hypothesis, $d\Lambda_{NR}(u, A_1) = d\Lambda_{NR}(u)$, so does not depend on A_1 ; similarly, $d\Lambda_R(u, A_1, \mathcal{T}_2, A_2) = d\Lambda_R(u)$, so does not depend on A_1, \mathcal{T}_2, A_2 . However, $d\Lambda_{NR}(u)$ need not be equal to $d\Lambda_R(u)$. Thus, under these generative scenarios,

$$\begin{aligned} E\{dN(u) \mid H(u^-)\} &= [d\Lambda_{NR}(u)\{1 - I(\kappa \geq 2, \mathcal{T}_2 \leq u)\} \\ &\quad + d\Lambda_R(u)I(\kappa \geq 2, \mathcal{T}_2 \leq u)]Y(u), \end{aligned}$$

in which case

$$\begin{aligned} E\{dM(u) \mid H(u^-)\} &= [d\Lambda_{NR}(u)\{1 - I(\kappa \geq 2, \mathcal{T}_2 \leq u)\} \\ &\quad + d\Lambda_R(u)I(\kappa \geq 2, \mathcal{T}_2 \leq u) - d\Lambda_0(u)]Y(u). \end{aligned} \tag{D.11}$$

(D.11) is not equal to zero unless $d\Lambda_{NR}(u) = d\Lambda_R(u)$, in which case

$$d\Lambda_{NR}(u) = d\Lambda_R(u) = d\Lambda_0(u),$$

and (D.11) equals zero. From Section A, $E\{\Omega(u, d^j)dM(u)\} = 0$, which is the basis of our approach; however, as the above demonstrates, $E\{\Omega(u, d^j)dM(u) \mid H(u^-)\}$ does not necessarily equal to zero unless $d\Lambda_{NR}(u) = d\Lambda_R(u)$.

The fact that $dM(u)$ is not necessarily a $H(u^-)$ martingale increment does not affect the unbiasedness of the vector of paired comparisons on which the test statistic of Kidwell and Wahed (2013) is based, but may impact the relevance of the authors' derivation of the covariance matrix of this vector, which depends on the assumed martingale structure. As we discuss further in Section F, this feature may underlie the simulation results reported in Section 3.

E. Second Order Correction to $\widehat{\Sigma}$

As discussed in Section 2.3, in small samples, the proposed test may be anticonservative. This feature is a consequence of the fact that the estimator $\widehat{\Sigma}$ for the asymptotic covariance matrix Σ of \mathfrak{T} understates the uncertainty in the components of \mathfrak{T} in finite samples when n is not sufficiently large. Such behavior is not uncommon with methods based on first-order semiparametric theory.

Accordingly, to improve the finite-sample performance of the test so that it achieves the nominal level of significance, we propose a second-order correction to the estimator for Σ in the spirit of similar corrections in other contexts (e.g. Kauermann and Carroll, 2001; Schaubel, 2005; Wang et al., 2023). Because we have observed anticonservatism of the test in simulations of SMARTs with small sample sizes in which the randomization probabilities were taken to be known or estimated, for simplicity, we present the argument leading to the corrected estimator for Σ in the case that the randomization probabilities are known. The same correction tactic can be used with estimated randomization probabilities and with inclusion of additional covariates to gain efficiency, as demonstrated in Section D.

We present a heuristic argument leading to the proposed correction. Recall that

$$\begin{aligned} d\widehat{\Lambda}_0(u) &= \frac{\sum_{i=1}^n \sum_{j=1}^D \Omega(u, d^j) dN_i(u)}{\sum_{i=1}^n \bar{Y}_i(u)}, \\ \widehat{q}(u, d^j) &= \frac{\sum_{i=1}^n \Omega_i(u, d^j) Y_i(u)}{\sum_{i=1}^n \bar{Y}_i(u)} \end{aligned}$$

where $\bar{Y}_i(u) = \sum_{j=1}^D \Omega_i(u, d^j) Y_i(u)$. As before, let $q(u, d^j)$ be the limit in probability of $\widehat{q}(u, d^j)$. For brevity, define

$$dM_i(u, \Lambda_0) = dN_i(u) - d\Lambda_0(u) Y_i(u).$$

Then, from (13), write \mathfrak{T}_i^j as

$$\Psi_i(d^j; q, \Lambda_0) = \int_0^\infty \left\{ \Omega_i(u, d^j) - q(u, d^j) \sum_{j'=1}^D \Omega_i(u, d^{j'}) \right\} dM_i(u, \Lambda_0), \quad (\text{E.1})$$

and let

$$\Psi_i(q, \Lambda_0) = \{\Psi_i(d^1; q, \Lambda_0), \dots, \Psi_i(d^{D-1}; q, \Lambda_0)\}^T,$$

which is the same as \mathfrak{T}_i , so that the asymptotic covariance matrix of $n^{-1/2}\mathfrak{T} = n^{-1/2} \sum_{i=1}^n \mathfrak{T}_i = n^{-1/2} \sum_{i=1}^n \Psi_i(q, \Lambda_0)$ can be approximated to first order by

$$n^{-1}\Sigma = n^{-1} \sum_{i=1}^n \{\Psi_i(q, \Lambda_0) \Psi_i(q, \Lambda_0)^T\}. \quad (\text{E.2})$$

We propose estimating (E.2) by

$$n^{-1} \sum_{i=1}^n \{\Psi_i(\hat{q}, \hat{\Lambda}_0) \Psi_i(\hat{q}, \hat{\Lambda}_0)^T\}. \quad (\text{E.3})$$

To identify the source of the finite-sample bias and to correct it, write

$$\Psi_i(\hat{q}, \hat{\Lambda}_0) = \Psi_i(q, \Lambda_0) - \{\Psi_i(q, \Lambda_0) - \Psi_i(q, \hat{\Lambda}_0)\} - \{\Psi_i(q, \hat{\Lambda}_0) - \Psi_i(\hat{q}, \hat{\Lambda}_0)\},$$

so that the estimator (E.3) can be written as

$$\begin{aligned} n^{-1} \sum_{i=1}^n \{\Psi_i(\hat{q}, \hat{\Lambda}_0) \Psi_i(\hat{q}, \hat{\Lambda}_0)^T\} &= n^{-1} \sum_{i=1}^n \{\Psi_i(q, \Lambda_0) \Psi_i(q, \Lambda_0)^T\} \\ &\quad - n^{-1} \sum_{i=1}^n \left[\Psi_i(q, \Lambda_0) \{\Psi_i(q, \Lambda_0) - \Psi_i(q, \hat{\Lambda}_0)\}^T \right] \end{aligned} \quad (\text{E.4})$$

$$\begin{aligned} &\quad - n^{-1} \sum_{i=1}^n \left[\Psi_i(q, \Lambda_0) \{\Psi_i(q, \Lambda_0) - \Psi_i(q, \hat{\Lambda}_0)\}^T \right]^T \\ &\quad - n^{-1} \sum_{i=1}^n \left[\Psi_i(q, \Lambda_0) \{\Psi_i(q, \hat{\Lambda}_0) - \Psi_i(\hat{q}, \hat{\Lambda}_0)\}^T \right] \end{aligned} \quad (\text{E.5})$$

$$\begin{aligned} &\quad - n^{-1} \sum_{i=1}^n \left[\Psi_i(q, \Lambda_0) \{\Psi_i(q, \hat{\Lambda}_0) - \Psi_i(\hat{q}, \hat{\Lambda}_0)\}^T \right]^T \\ &\quad + \text{smaller order terms}, \end{aligned} \quad (\text{E.6})$$

where we disregard the terms in (E.6) as they involve sample averages of the product of the differences $\{\Psi_i(q, \Lambda_0) - \Psi_i(q, \hat{\Lambda}_0)\}$ and $\{\Psi_i(q, \hat{\Lambda}_0) - \Psi_i(\hat{q}, \hat{\Lambda}_0)\}$.

First consider (E.4) and define for brevity

$$A_i(u, q, d^j) = \left\{ \Omega_i(u, d^j) - q(u, d^j) \sum_{j'=1}^D \Omega_i(u, d^{j'}) \right\},$$

and consider a typical term in the matrix in a summand of (E.4). I.e., for regimes d^j and

$d^{j'}$, consider

$$\Psi_i(d^j; q, \Lambda_0) \{ \Psi_i(d^{j'}; q, \Lambda_0) - \Psi_i(d^{j'}; q, \hat{\Lambda}_0) \},$$

which by (E.1) is equal to

$$\int_0^\infty A_i(u, q, d^j) dM_i(u, \Lambda_0) \int_0^\infty A_i(u, q, d^{j'}) \{ d\hat{\Lambda}_0(u) - d\Lambda_0(u) \} Y_i(u). \quad (\text{E.7})$$

But

$$\{ d\hat{\Lambda}_0(u) - d\Lambda_0(u) \} = \frac{n^{-1} \sum_{\ell=1}^n \sum_{j'=1}^D \Omega_\ell(u, d^{j'}) dM_\ell(u, \Lambda_0)}{n^{-1} \sum_{\ell=1}^n \bar{Y}_\ell(u)} \quad (\text{E.8})$$

Note that the denominator of (E.8), $n^{-1} \sum_{\ell=1}^n \bar{Y}_\ell(u)$, will converge in probability as $n \rightarrow \infty$, so we can regard this quantity as fixed in subsequent arguments, as presumably the difference between it and its limit in probability will be a second order effect.

Thus, interchanging sums, (E.7) is equal to

$$n^{-1} \sum_{\ell=1}^n \frac{\left\{ \int_0^\infty A_i(u, d^j) dM_i(u, \Lambda_0) \int_0^\infty A_i(u, q, d^{j'}) \sum_{j'=1}^D \Omega_\ell(u, d^{j'}) dM_\ell(u, \Lambda_0) \right\} Y_i(u)}{n^{-1} \sum_{\ell=1}^n \bar{Y}_\ell(u)}. \quad (\text{E.9})$$

The expectation of a summand in (E.9) when $\ell \neq i$ is zero; thus, the expectation of (E.9) is the same as the expectation of

$$\left\{ \int_0^\infty A_i(u, q, d^j) dM_i(u, \Lambda_0) \right\} \frac{\left\{ \int_0^\infty A_i(u, q, d^j) \sum_{j'=1}^D \Omega_i(u, d^{j'}) dM_i(u, \Lambda_0) \right\}}{n^{-1} \sum_{\ell=1}^n \bar{Y}_\ell(u)},$$

where we have used the fact that $dM_i(u, \Lambda_0) Y_i(u) = dM_i(u, \Lambda_0)$.

Based on these developments, letting $\mathbf{A}_i(u, q) = \{A_i(u, q, d^1), \dots, A_i(u, q, d^{D-1})\}^T$, we propose estimating (E.4) by

$$n^{-2} \sum_{i=1}^n \left\{ \int_0^\infty \mathbf{A}_i(u) dM_i(u, \Lambda_0) \right\} \frac{\left\{ \int_0^\infty \mathbf{A}_i(u, q)^T \sum_{j'=1}^D \Omega_i(u, d^{j'}) dM_i(u, \Lambda_0) \right\}}{n^{-1} \sum_{\ell=1}^n \bar{Y}_\ell(u)},$$

where in practice we replace $q(u, d^j)$ and $\Lambda_0(u)$ by the estimators $\hat{q}(u, d^j)$ and $\hat{\Lambda}_0(u)$. Defining further

$$\mathbf{G}_i(q, \Lambda_0) = \frac{\left\{ \int_0^\infty \mathbf{A}_i(u, q) \sum_{j'=1}^D \Omega_i(u, d^{j'}) dM_i(u, \Lambda_0) \right\}}{n^{-1} \sum_{\ell=1}^n \bar{Y}_\ell(u)},$$

and noting that

$$\int_0^\infty \mathbf{A}_i(u, q) dM_i(u, \Lambda_0) = \boldsymbol{\Psi}_i(q, \Lambda_0),$$

we estimate (E.4) by

$$n^{-2} \sum_{i=1}^n \Psi_i(q, \Lambda_0) \mathbf{G}_i(q, \Lambda_0)^T,$$

where in practice we replace $q(u, d^j)$ and $\Lambda_0(u)$ by the estimators $\hat{q}(u, d^j)$ and $\hat{\Lambda}_0(u)$.

A similar argument can be used to derive an estimator for (E.5). First note that (E.5) is equal to

$$n^{-1} \sum_{i=1}^n [\Psi_i(q, \Lambda_0) \{\Psi_i(q, \Lambda_0) - \Psi_i(\hat{q}, \Lambda_0)\}^T] + \text{smaller order terms}.$$

Thus, consider a typical term in the matrix in a summand; i.e., for regimes d^j and $d^{j'}$,

$$\Psi_i(d^j; q, \Lambda_0) \{\Psi_i(d^{j'}; q, \Lambda_0) - \Psi_i(d^{j'}; \hat{q}, \Lambda_0)\},$$

which is equal to

$$\left\{ \int_0^\infty A_i(u, q, d^j) dM_i(u, \Lambda_0) \right\} \int_0^\infty \{\hat{q}(u, d^{j'}) - q(u, d^{j'})\} \sum_{j'=1}^D \Omega_i(u, d^{j'}) dM_i(u, \Lambda_0). \quad (\text{E.10})$$

It is straightforward to show that $\{\hat{q}(u, d^{j'}) - q(u, d^{j'})\}$ is equal to

$$n^{-1} \sum_{\ell=1}^n \frac{\Omega_\ell(u, d^{j'}) Y_\ell(u) - q(u, d^{j'}) \sum_{j''=1}^D \Omega_\ell(u, d^{j''}) Y_\ell(u)}{n^{-1} \sum_{\ell=1}^n \bar{Y}_\ell(u)}.$$

Thus, substituting, (E.10) equals

$$\begin{aligned} n^{-1} \sum_{\ell=1}^n \left\{ \int_0^\infty A_i(u, q, d^j) dM_i(u, \Lambda_0) \right\} & \frac{\left\{ \Omega_\ell(u, d^{j'}) Y_\ell(u) - q(u, d^{j'}) \sum_{j''=1}^D \Omega_\ell(u, d^{j''}) Y_\ell(u) \right\}}{n^{-1} \sum_{\ell=1}^n \bar{Y}_\ell(u)} \\ & \times \sum_{j''=1}^D \Omega_i(u, d^{j''}) dM_i(u, \Lambda_0). \end{aligned} \quad (\text{E.11})$$

As above, when $\ell \neq i$, the expectation of a summand in (E.11) is zero. Thus, using $dM_i(u, \Lambda_0) Y_i(u) = dM_i(u, \Lambda_0)$, we replace (E.11) by

$$\left\{ \int_0^\infty A_i(u, q, d^j) dM_i(u, \Lambda_0) \right\} \frac{\Omega_i(u, d^{j'}) - q(u, d^{j'}) \sum_{j''=1}^D \Omega_i(u, d^{j''})}{n^{-1} \sum_{\ell=1}^n \bar{Y}_\ell(u)} \sum_{j''=1}^D \Omega_i(u, d^{j''}) dM_i(u, \Lambda_0).$$

Then, using the definitions of $\mathbf{A}_i(u, q)$ and $\mathbf{G}_i(q, \Lambda_0)$ above, we estimate (E.5) by

$$n^{-2} \sum_{i=1}^n \Psi_i(q, \Lambda_0) \mathbf{G}_i(q, \Lambda_0)^T,$$

where in practice we replace $q(u, d^j)$ and $\Lambda_0(u)$ by the estimators $\hat{q}(u, d^j)$ and $\hat{\Lambda}_0(u)$.

Collecting these results, we propose the bias-corrected estimator for Σ given by

$$\begin{aligned} n^{-1} \sum_{i=1}^n \{\Psi_i(\hat{q}, \hat{\Lambda}_0) \Psi_i(\hat{q}, \hat{\Lambda}_0)^T\} + n^{-2} \sum_{i=1}^n \left\{ 2\Psi_i(\hat{q}, \hat{\Lambda}_0) \mathbf{G}_i(\hat{q}, \hat{\Lambda}_0)^T + 2\mathbf{G}_i(\hat{q}, \hat{\Lambda}_0) \Psi_i(\hat{q}, \hat{\Lambda}_0)^T \right\} \\ = \hat{\Sigma} + n^{-1} \left[n^{-1} \sum_{i=1}^n \left\{ 2\hat{\mathfrak{T}}_i \mathbf{G}_i(\hat{q}, \hat{\Lambda}_0)^T + 2\mathbf{G}_i(\hat{q}, \hat{\Lambda}_0) \hat{\mathfrak{T}}_i^T \right\} \right], \end{aligned} \quad (\text{E.12})$$

where $\hat{\Sigma}$ is our proposed estimator and $\hat{\mathfrak{T}}_i = \Psi_i(\hat{q}, \hat{\Lambda}_0)$. The second term in (E.12) effects a bias correction that will be nonnegligible when n is not large, so that (E.12) provides a more faithful representation of the uncertainty in estimation of Σ .

If in a SMART the randomization probabilities are estimated or modeled as discussed in Section D, with the possible addition of basis functions of the history to enhance efficiency/power, to obtain a bias-corrected covariance matrix estimator, form all of the quantities above involving $\Omega(u, d^j)$, $j = 1, \dots, D$, by substituting the fitted models $\omega_k(\mathbf{h}_k, a_k; \hat{\gamma})$, $k = 1, \dots, K$, and replace $\hat{\Sigma}$ and $\hat{\mathfrak{T}}_i$ in (E.12) by $\hat{\Sigma}_\gamma$ and $\hat{\mathfrak{T}}_i^R(\hat{\gamma})$.

F. Simulation Details

F.1. Implications of martingale property

We examine the implications of Section D.4, namely, that the martingale property need not hold, for the data generative Scenarios 1-3 in the simulation in Section 3, which may offer insight into the nature of the simulation results.

First consider Scenarios 1(a) and 2(a) under the null hypothesis; as noted in Section 3, Scenario 1(a) is the first null scenario of Kidwell and Wahed (2013). Let $\pi_R = P(R = 1)$; $\pi_R = 0.4$ in Scenarios 1(a) and 2(a). Because H_0 holds, we suppress the subscripts indicating treatment; thus, for $R = 0$, let T^{NR} , the potential event time, be $\text{exponential}(\lambda_1)$. If $R = 1$, let the potential time to response, T^R , be $\text{exponential}(\lambda_2)$ and the potential time to event, T^{RE} , be $\text{exponential}(\lambda_3)$. Then it is straightforward to show that the hazard of experiencing

the event prior to response at time u is given by

$$\frac{(1 - \pi_R)\lambda_1 \exp(-\lambda_1 u)}{(1 - \pi_R) \exp(-\lambda_1 u) + \pi_R \exp(-\lambda_2 u)}. \quad (\text{F.1})$$

The hazard of experiencing the event after response ($R = 1$) is equal to λ_3 from above. According to Section D.4, the martingale property will hold if (F.1) is equal to λ_3 . Moreover, it can be shown that

$$\lambda_0(u) = \frac{(1 - \pi_R)\lambda_1 \exp(-\lambda_1 u) + \pi_R \lambda_2 \lambda_3 \{\exp(-\lambda_3 u) - \exp(-\lambda_2 u)\}/(\lambda_2 - \lambda_3)}{(1 - \pi_R) \exp(-\lambda_1 u) + \pi_R \{\lambda_2 \exp(-\lambda_3 u) - \lambda_3 \exp(-\lambda_2 u)\}/(\lambda_2 - \lambda_3)}. \quad (\text{F.2})$$

In Scenario 1(a), $\lambda_1 = 1/0.91 = 1.099$, $\lambda_2 = 1/0.5 = 2$, and $\lambda_3 = 1$. In Figure 5, for these values and $\pi_R = 0.4$ we plot (F.1) (dashed line), λ_3 (solid line), and (F.2) (dotted line). The hazard in (F.1) differs from λ_3 over most of the time range, but the greatest disparity, for small u , is not substantial. We conjecture that this relatively mild departure from the martingale property is reflected in the fact that the test of Kidwell and Wahed (2013) achieves the nominal level. In contrast, Figure 6 shows the same plot for Scenario 2(a), for which $\lambda_1 = 1/0.91 = 1.099$, $\lambda_2 = 1/0.5 = 2$, and $\lambda_3 = 1/3$. Here, the disparity between λ_3 (solid) and (F.1) (dashed) is substantial, and we conjecture that the conservatism of the test of Kidwell and Wahed (2013) in this case, which persists as the sample size increases, is a consequence of this feature.

[Figure 5 about here.]

[Figure 6 about here.]

Consider now Scenario 3 under the null hypothesis ($\zeta = 0$) in the simplified case in which there are no covariate effects, so that $\psi = 0$. Under this generative scenario, the hazard of experiencing the event prior to response at time u is given by $\lambda_1 = \exp(\alpha_{1D})$ and the hazard of experiencing the event after response ($R = 1$) is given by $\lambda_3 = \exp(\alpha_{2AL})$. Moreover, the hazard for the potential time to Decision 2 $\lambda_2 = \exp(\alpha_{1SS})$, and

$$\lambda_0(u) = \frac{(\lambda_1 + \lambda_2)(\lambda_1 - \lambda_3) \exp\{-(\lambda_1 + \lambda_2)u\} + \lambda_2 \lambda_3 \exp(-\lambda_3 u)}{(\lambda_1 - \lambda_3) \exp\{-(\lambda_1 + \lambda_2)u\} + \lambda_2 \exp(-\lambda_3 u)}. \quad (\text{F.3})$$

According to Section D.4, the martingale property holds in this setting if $\lambda_1 = \lambda_3$. In Scenario 3(a), $\alpha_{1D} = \alpha_{2AL} = -5.5$; thus, without covariate effects ($\psi = 0$), the martingale property holds exactly, and likely holds approximately when covariate effects are included as in Section 3 ($\psi = 1.5$). As seen in Table 1, the test of Kidwell and Wahed (2013) achieves the nominal level, as expected under these conditions. In Scenario 3(b), $\alpha_{1D} = -4.5$ and $\alpha_{2AL} = -5.5$, so that the martingale property does not hold exactly or approximately; we conjecture that the conservatism of the test of Kidwell and Wahed (2013) in this case, which persists as the sample size increases, is a consequence of this feature. In Scenario 3(c), $\alpha_{1D} = -5.5$ and $\alpha_{2AL} = -3.5$, so that the martingale property does not hold exactly or approximately. Again, we conjecture that the anti-conservatism of the test of Kidwell and Wahed (2013) reflects this feature.

F.2. Details for Scenarios 4 and 5

Scenario 4, which is based on the SMART design in Figure 3, with an additional control regime, is similar to Scenario 3, with the following modifications to incorporate the control regime. Code the control as $a_1 = 2$, so that $\mathcal{A}_1 = \{0, 1, 2\}$. We generated A_1 as multinomial with probabilities $1/3, 1/3, 1/3$ for $a_1 = 0, 1, 2$, respectively. For given $\alpha_{1D} = -5.5$, $\alpha_{1SS} = -4.2$, $\alpha_{2AL} = -5.5$, $\psi = 1.5$, and ζ , we took $\boldsymbol{\theta}_{1D} = (\alpha_{1D}, 0.5\psi, 0.5\psi, -0.26\zeta, 0.15\zeta)^T$ and $\boldsymbol{\theta}_{1SS} = (\alpha_{1SS}, 0.5\psi, 0.5\psi, 0.24\zeta - 0.13\zeta)^T$, generated potential event time T_D as $\text{exponential}(\lambda_{1D})$, $\lambda_{1D} = \exp\{\theta_{1D,1} + \theta_{1D,2}X_{11} + \theta_{1D,3}X_{12} + \theta_{1D,4}I(A_1 = 1) + \theta_{1D,5}I(A_1 = 2)\}$ and potential time to Decision 2 T_{SS} as $\text{exponential}(\lambda_{1SS})$, $\lambda_{1SS} = \exp\{\theta_{1SS,1} + \theta_{1SS,2}X_{11} + \theta_{1SS,3}X_{12} + \theta_{1SS,4}A_1\}$, and took $S = \min(T_D, T_{SS})$ and $R = I(T_{SS} < T_D)$. If $R = 1$, with $\boldsymbol{\theta}_{X_2} = (0.2, 0.5\psi, 0.4\psi, 0.12\zeta, 0.1\zeta)^T$ and $\boldsymbol{\theta}_{2AL} = (\alpha_{2AL}, 0.5\psi, -0.52\psi, 0.6\psi, -0.1\zeta, 0.15\zeta, -0.11\zeta)^T$, we generated X_2 as Bernoulli(p_{X_2}), $p_{X_2} = \text{expit}\{\theta_{X_2,1} + \theta_{X_2,2}X_{11} + \theta_{X_2,3}X_{12} + \theta_{X_2,4}I(A_1 = 1) + \theta_{X_2,5}I(A_1 = 2)\}$, A_2 as Bernoulli(0.5), and “added life” post-response T_{AL} as $\text{exponential}(\lambda_{2,AL})$,

$\lambda_{1AL} = \exp\{\theta_{1AL,1} + \theta_{1AL,2}X_{11} + \theta_{1AL,3}X_{12} + \theta_{1AL,4}X_2 + \theta_{1AL,5}I(A_1 = 1) + \theta_{1AL,6}I(A_1 = 2) + \theta_{1AL,7}A_2I(A_1 < 2)\}$. All other features of the scenario are as in Section 3.

For Scenario 5, data generation is as in Scenario 3 at the first stage of the design, with $\alpha_{1D} = -5.5$ and $\alpha_{1SS} = -3.5$, $\psi = 1.5$, and $\boldsymbol{\theta}_{1D}$ and $\boldsymbol{\theta}_{1SS}$ as in Scenario 3 but with potential event time T_D as $\text{exponential}(\lambda_{1D})$, $\lambda_{1D} = \exp(\theta_{1D,1} + \theta_{1D,2}X_{11} + \theta_{1D,3}X_{12} + \theta_{1D,4}A_1)$ and potential time to Decision 2 T_{SS} as $\text{exponential}(\lambda_{1SS})$, $\lambda_{1SS} = \exp(\theta_{1SS,1} + \theta_{1SS,2}X_{11} + \theta_{1SS,3}X_{12} + \theta_{1SS,4}A_1)$. We then took $S = \min(T_D, T_{SS})$ as before and additionally $\Gamma_{SS} = I(T_{SS} < T_D)$. For subjects who would reach Decision 2, with $\Gamma_{SS} = 1$, we generated response status R as $\text{Bernoulli}(p_R)$, where $p_R = \text{expit}(0.3 + 0.15X_{11} + 0.15X_{12} + 0.2\zeta A_1)$, and X_2 as in Scenario 3. For these subjects with $\Gamma_{SS} = 1$, we generated A_2 as $\text{Bernoulli}(0.5)$ within their observed value of (A_1, R) . Then with $\boldsymbol{\theta}_{2AL} = (\alpha_{2AL}, 0.5\psi, -0.52\psi, 0.6\psi, -0.1\zeta, -0.11\zeta, -0.3\zeta)^T$, we generated “added life” post-response T_{AL} as $\text{exponential}(\lambda_{2,AL})$, $\lambda_{1AL} = \exp\{\theta_{1AL,1} + \theta_{1AL,2}X_{11} + \theta_{1AL,3}X_{12} + \theta_{1AL,4}X_2 + \theta_{1AL,5}A_1 + \theta_{1AL,6}A_2 + \theta_{1AL,7}R\}$. We then took $T = (1 - \Gamma_{SS})T_D + \Gamma_{SS}(T_{SS} + T_{AL})$ and, with $C \sim \text{uniform}(0, c_{\max})$, $U = \min(T, C)$, $\Delta = I(T \leq C)$. If $\Gamma_{SS} = 1$ but $C < T_{SS}$ or $\Gamma_{SS} = 0$, take R to be undefined. For subjects for whom $\Gamma_{SS} = 1$ and $C \geq T_{SS}$, $\mathcal{T}_2 = T_{SS}$ and $\kappa = 2$; if $\Gamma_{SS} = 1$ and $C < T_{SS}$ or $\Gamma_{SS} = 0$, $\kappa = 1$.

F.3. Simulation studies of tests of pairwise comparisons of regimes

The test statistic of Kidwell and Wahed (2013) involves a (3×1) vector, where each component addresses a pairwise comparison of the hazards for two of the four regimes in a SMART analogous to that in Figure 3 without the additional control regime. Specifically, as in the figure, represent these regimes as being of the form “Give treatment a initially; if the event does not occur before response status is ascertained and nonresponse, continue, otherwise, if response, give treatment b ,” the four regimes correspond to $(a, b) = (0, 0), (0, 1), (1, 0), (1, 1)$.

Denoting these as Regimes 1, 2, 3, and 4 in this order, the three components involve the comparisons of 3 versus 4, 2 versus 4, and 1 versus 4; that is, Regime 4 is the reference regime against which the other three regimes are compared. The comparison of Regimes 3 and 4 involves “shared path” regimes starting with the same stage 1 treatment, while the other two comparisons start with different stage 1 treatments. The test statistic of Kidwell and Wahed (2013) is formed as a quadratic form involving this (3×1) vector and an approximation to its sampling covariance matrix using martingale theory, which, as discussed in Section 2.4, may be violated. It is thus possible to construct from these elements three test statistics as a component of the vector divided by its standard error obtained from this sampling covariance matrix, where these test statistics address the comparisons of Regimes 3 versus 4, 2 versus 4, and 1 versus 4, respectively.

The above configuration is the situation in simulation Scenarios 1 - 3 in Section 3. Study C9710,, depicted in Figure 1, is analogous, involving four embedded regimes of the form “Give consolidation therapy a ; if subject completes consolidation (responder) before the event occurs, give maintenance therapy b ,” which we denote as Regimes 1, 2, 3, and 4 as $(a, b) = (0, 0), (0, 1), (1, 0), (1, 1)$.

To evaluate the performance of the proposed methods and the test of Kidwell and Wahed (2013) for making pairwise comparisons, we considered Scenario 1(a), which as in Section F is expected to be robust to departure from the martingale property; Scenario 2(a), which involves a strong departure from the martingale property; Scenario 3(a), for which the martingale property holds roughly except for covariate associations; and Scenario 3(c), which reflects a departure from the martingale property and includes covariate associations. For each scenario, we used the test statistics obtained from the overall test statistic of Kidwell and Wahed (2013) as described above and the various versions of the proposed test statistic

denoted as $\mathbb{Z}_{U,\text{nocov}}$, $\mathbb{Z}_{U,\text{nocov}}$, $\mathbb{Z}_{U,\text{cov}}$, and $\mathbb{Z}_{C,\text{cov}}$, where \mathcal{D} was taken to be the subset of embedded regimes involved in the indicated pairwise comparison (so $D = 2$).

Table 3 shows the results. Under the null hypothesis, under Scenarios 1(a) and 3(a), the proposed methods with using the bias-corrected covariance matrix and the test statistics of Kidwell and Wahed (2013) mostly achieve the nominal level, reflecting for the latter that the martingale property is not significantly violated. However, under Scenarios 2(a) and 3(c), although the proposed methods continue to achieve the nominal level, that of Kidwell and Wahed (2013) for testing the “shared path” comparison (3 versus 4) in Scenario 2(a) is anti-conservative, suggesting that the anti-conservative performance of the overall test shown in Table 1 stems from this comparison. Likewise, under Scenario 3(c), although the test of Kidwell and Wahed (2013) achieves the nominal level for the “shared path” comparison (3 versus 4), the non-shared path comparisons (2 versus 4, 1 versus 4) exhibit anti-conservatism, suggesting that the performance of the overall test shown in Table 1 reflects this behavior. We also show power under the same alternatives in Section 3 for Scenarios 3(a) and 3(c), which involve covariates associated with the event time; the comparison of Regimes 2 versus 4 is omitted under Scenario 3(c) because the hazards for these regimes are very similar, so that power is extremely low using all test statistics. As for the proposed tests of the overall null hypothesis in (1), the proposed tests of pairwise comparisons show enhanced power when covariates are incorporated.

[Table 3 about here.]

F.4. Simulation study of comparison of more complex regimes

To demonstrate that the proposed methods can be used to compare the regimes in an arbitrary set of regimes that are “feasible” given the available data in the sense discussed in Tsiatis et al. (2020, Section 6.2.3), consider Scenario 3(a) of Section 3, where $\mathcal{A}_1 = \{0, 1\}$ and $\mathcal{A}_2 = \{0, 1\}$. Recall that by construction the covariates are associated with the event

time outcome. We take the set of regimes of interest to be $\mathcal{D} = \{d^1, d^2, d^3\}$ ($D = 3$), where the regimes are defined as follows:

- Regime 1, d^1 , with rules $d_1^1(\mathbf{h}_1) = I(X_{12} \geq 0.3)$, $d_2^1(\mathbf{h}_2) = I(X_{12} \geq 0.4, X_2 = 1, R = 1)$
- Regime 2, d^2 , with rules $d_1^2(\mathbf{h}_1) = I(X_{12} \leq 0.5)$, $d_2^2(\mathbf{h}_2) = I(X_{12} \geq 0.6, X_2 = 1, R = 1)$
- Regime 3, d^3 , with rules $d_1^3(\mathbf{h}_1) = I(X_{12} \geq 0.7)$, $d_2^3(\mathbf{h}_2) = I(X_{12} \geq 0.8, X_2 = 0, R = 1)$.

The choice of these regimes is completely arbitrary and for demonstration only.

Table 4 shows the results under the null hypothesis of no difference in hazard rate among these three regimes and demonstrates that the proposed methods yield a test achieving the nominal level of significance.

[Table 4 about here.]

G. Data Analysis Details

G.1. Data definitions and data cleaning

The data from North American Leukemia Intergroup Study C9710 provided to us by the Alliance for Clinical Trials in Oncology comprise information on 538 subjects; this data set is the same as that considered by Hager et al. (2018). Ten (10) baseline covariates (components of \mathbf{X}_1) were ideally collected on each subject at the time of registration into the trial: age, gender, race, ethnicity, Eastern Cooperative Oncology Group (ECOG) performance status, risk group, white blood cell count, platelet count, serum creatinine, and hemoglobin. Table 5 shows these covariates. For responders, \mathbf{X}_2 includes variables summarizing adverse events and toxicities occurring during induction or consolidation therapy. We consider only adverse events experienced by at least 5% of patients. Table 6 shows the adverse events, which are coded with an eight-digit Medical Dictionary for Regulatory Activities (medDRA) code. In the data, the adverse events were recorded as occurring during induction therapy (coded by “I”), during consolidation therapy (coded by “C”), and during either induction or

consolidation therapy (coded by “IC”). Thus, the binary variable “IC_90004060” represents whether or not hemorrhage or bleeding with grade 3 or 4 thrombocytopenia occurred during either induction or consolidation therapy. There are 46 such variables in \mathbf{X}_2 ; three of the variables are trinary; all others are binary.

[Table 5 about here.]

[Table 6 about here.]

For the data analysis reported in Section 4, we considered a subset of these data, similar to Hager et al. (2018). First, the following subjects were removed from the data set: 57 subjects deemed ineligible according to the age criterion in Powell et al. (2010), 7 subjects with more than two covariates missing, and 6 subjects for whom the date of initiation of induction therapy is missing. Fifteen (15) subjects are missing the start date of maintenance therapy; the actual event or censoring time for these subjects was artificially censored at the start date of consolidation therapy. One (1) such subject is also missing the start date of consolidation therapy; this subject was also removed from the data set (Hager et al. (2018) did not remove this subject). After these deletions, $n = 467$ subjects were available for analysis.

Of these subjects, the first 50 to enroll in the study had different maintenance treatment options; of the 47 of these subjects not already removed, all reached stage 2, and the actual event or censoring time for these subjects was artificially censored at the start date of maintenance therapy. For four (4) other subjects, the start date for maintenance therapy was recorded as being before or equal to the date of registration in the study; the actual event/censoring time for these subjects was artificially censored at the date of start of consolidation therapy.

Taking into account all of these conventions, among the $n = 467$ subjects, 310 reached stage 2 and were randomized to maintenance therapy options.

As in Hager et al. (2018), several of the baseline covariates were redefined as follows:

- The number of race groups is reduced to only include “White,” “Hispanic American,” “Black/African American,” and “Other.” Patients previously classified as “Asian,” “Native Hawaiian or Pacific Islander,” “American Indian or Alaska Native,” “Indian Subcontinent,” or “Multiple Races Reported” are classified as “Other.”
- 1 subject has a platelet count of 5300, which is much higher than those for all other subjects, who had values in the range 1–232. This observation was divided by 100 for consistency with the range given in Powell et al. (2010).
- 4 subjects have hemoglobin levels of 87, 92, 81, and 80, which are much higher than those for the rest of the subjects, who had values in the range of 4.3–14.6. It is believed that these values were entered in units of g/L instead of g/dL, so we divided these hemoglobin observations by 10.
- 7 subjects have creatinine levels of 76, 95, 87, 92, 90, 52, and 53, which are much higher than those for the rest of the subjects, who had values in a range of 0.1–10.4. It is believed these were entered in units of $\mu\text{mol/L}$ instead of mg/dL. These creatinine observations are divided by 88.4 to correct the units.

The data after these adjustments are consistent with the information presented in Powell et al. (2010).

Of the $n = 467$ subjects, 446 have complete data on all baseline covariates, and the remainder have missing values for no more than 2 covariates. The missing values were imputed as follows:

- Race is set to “Other” for the 8 subjects for whom it is missing.
- 5 subjects are missing creatinine. A linear model to estimate creatinine using all other baseline covariates was fitted to the data from the complete cases and used to impute the missing values.
- 1 subject is missing white blood cell count (WBC). A linear model to estimate WBC using

all baseline covariates except for WBC and Risk group was fitted to the data from the complete cases and used to impute the missing WBC value.

- 4 subjects are missing ECOG performance status. A multinomial logistic regression model for ECOG performance status using all other baseline covariates was fitted to the data from the complete cases. The missing ECOG performance status values were imputed using this model.
- 4 subjects are missing hemoglobin. A linear model to estimate hemoglobin using all other baseline covariates was fitted to the data from the complete cases and used to impute the missing values.

G.2. Data analysis

At stage 1, let $A_1 = 0$ if a subject was randomized to ATRA consolidation therapy and $A_1 = 1$ if randomized to ATRA+Arsenic Trioxide. Here, a subject is a “nonresponder” if the subject experienced the event or was censored before completing consolidation therapy, with $\kappa = 1$. A subject is a “responder” if the subject completed consolidation without experiencing the event or censoring, $\kappa = 2$; for such subjects, let $A_2 = 0$ if a subject was randomized at stage 2 to ATRA maintenance therapy and $A_2 = 1$ if randomized to ATRA+Mtx+MP. For consistency with the examples in Sections B and D, define $R_2 = I(\kappa = 2)$, although this definition is redundant, as all subjects for whom $\kappa = 2$ are “responders.”

For the proposed methods, as in Section D, we estimated the randomization probabilities by positing and fitting logistic regression models

$$\omega_1(\mathbf{h}_1, a_1; \gamma_1) = \left\{ \frac{\exp(\gamma_1)}{1 + \exp(\gamma_1)} \right\}^{I(a_1=1)} \left\{ \frac{1}{1 + \exp(\gamma_1)} \right\}^{I(a_1=0)}$$

at stage 1 and

$$\begin{aligned} \omega_2(\mathbf{h}_2, a_2; \gamma_2) &= \left\{ \frac{\exp(\gamma_{21})}{1 + \exp(\gamma_{21})} \right\}^{I(a_1=0, r_2=1, a_2=1)} \left\{ \frac{1}{1 + \exp(\gamma_{21})} \right\}^{I(a_1=0, r_2=1, a_2=0)} \\ &\times \left\{ \frac{\exp(\gamma_{22})}{1 + \exp(\gamma_{22})} \right\}^{I(a_1=1, r_2=1, a_2=1)} \left\{ \frac{1}{1 + \exp(\gamma_{22})} \right\}^{I(a_1=1, r_2=1, a_2=0)} \end{aligned}$$

at stage 2. Letting $\hat{\gamma}$ be the ML estimator for $\gamma = (\gamma_1, \gamma_{21}, \gamma_{22})^T$, as in Section D, to obtain our test statistic without incorporating covariates to gain efficiency, for each regime $j = 1, \dots, 4$, we performed a linear regression with dependent variable $\hat{\mathfrak{T}}_i^j(\hat{\gamma})$ and design matrix with i th row

$$\begin{aligned} & \left[\{I(A_{1i} = 1) - \text{expit}(\hat{\gamma}_1)\}, I(A_{1i} = 0, R_{2i} = 1, \kappa_i = 2) \{I(A_{2i} = 1) - \text{expit}(\hat{\gamma}_{21})\}, \right. \\ & \left. I(A_{1i} = 1, R_{2i} = 1, \kappa_i = 2) \{I(A_{2i} = 1) - \text{expit}(\hat{\gamma}_{22})\} \right] \end{aligned} \quad (\text{G.1})$$

to obtain the residuals $\hat{\mathfrak{T}}_i^{j,R}(\hat{\gamma})$ and thus $\hat{\Sigma}_\gamma$.

To attempt to enhance power by incorporating covariates, we informally examined associations between the covariates and outcome. To gain a sense of the extent to which components of the baseline covariates \mathbf{X}_1 in Table 5 are potentially associated with outcome, we fit separate proportional hazards models to the data (U, Δ) for the $n = 467$ subjects, where in each model we included each component of \mathbf{X}_1 as the sole covariate. Because the distribution of WBC is extremely skewed, we considered the logarithm of WBC as a covariate, and all discrete covariates were treated as categorical. From these fits, we identified $(X_{11}, X_{12}, X_{13}) = \{\log(\text{WBC}), I(\text{ECOG Performance Status} > 1), I(\text{Risk Group} > 2)\}$ as potentially associated with the EFS outcome. As X_{11} and X_{13} are highly associated owing to the definition of the latter, we opted to consider X_{11} and X_{12} as covariates for the purpose of gaining efficiency as discussed in Section D. Thus, analogous to (D.10), we defined the vector of basis functions $\widetilde{\mathbf{H}}_1 = (X_{11}, X_{12})^T$.

To gain an informal sense of the extent to which adverse event variables in \mathbf{X}_2 are associated with outcome, we considered only the 310 subjects who were observed to reach the second decision point ($\kappa = 2$), and fit separate proportional hazards models to the data (U, Δ) including each component of \mathbf{X}_2 as the sole covariate, treating each covariate as categorical. From these fits, we identified the binary variables $X_{21} = \text{I_10028813, Nausea}$, and $X_{22} = \text{IC_90004060, hemorrhage or bleeding with grade 3 or 4 neutropenia}$, as potentially associated with the EFS outcome. Thus, analogous to (D.10), we defined vectors of basis

functions $\widetilde{\mathbf{H}}_{21} = \widetilde{\mathbf{H}}_{22} = (X_{11}, X_{12}, X_{21}, X_{22})^T$, appended to the i th row of the design matrix in (G.1) the additional components

$$\begin{aligned} & \left[\{I(A_{1i} = 1) - \text{expit}(\widehat{\gamma}_1)\} \widetilde{\mathbf{H}}_1^T, I(A_{1i} = 0, R_{2i} = 1, \kappa_i = 2) \{I(A_{2i} = 1) - \text{expit}(\widehat{\gamma}_{21})\} \widetilde{\mathbf{H}}_{21}^T, \right. \\ & \left. I(A_{1i} = 1, R_{2i} = 1, \kappa_i = 2) \{I(A_{2i} = 1) - \text{expit}(\widehat{\gamma}_{22})\} \widetilde{\mathbf{H}}_{22}^T \right] \end{aligned}$$

and carried out the regression with dependent variable $\widehat{\mathfrak{T}}_i^j(\widehat{\gamma})$ and obtained the residuals $\widehat{\mathfrak{T}}_i^{j,R}(\widehat{\gamma})$ and thus $\widehat{\Sigma}_\gamma$ and the test statistic $\mathbb{Z}(\widehat{\gamma})$.

ACKNOWLEDGMENTS

The authors thank the Alliance for Clinical Trials in Oncology for providing the Study C9710 data. This research was supported by NIH grant R01CA280970.

REFERENCES

- Almirall, D., Nahum-Shani, I., Sherwood, N. E., and Murphy, S. A. (2014). Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research. *Translational Behavioral Medicine* **4**, 260–274.
- Bigirimurame, T., Uwimpuhwe, G., and Wason, J. (2022). Sequential multiple assignment randomized trial studies should report all key components: a systematic review. *Journal of Clinical Epidemiology* **142**, 152–160.
- Boos, D. D. (1992). On generalized score tests. *The American Statistician* **46**, 327–333.
- Feng, W. and Wahed, A. S. (2008). Supremum weighted log-rank test and sample size for comparing two-stage adaptive treatment strategies. *Biometrika* **95**, 695–707.
- Guo, X. and Tsiatis, A. A. (2005). A weighted risk set estimator for survival distributions in two-stage randomization designs with censored survival data. *The International Journal of Biostatistics* **1**, 1.
- Hager, R., Tsiatis, A. A., and Davidian, M. (2018). Optimal two-stage dynamic treatment

- regimes from a classification perspective with censored survival data. *Biometrics* **74**, 1180–1192.
- Kauermann, G. and Carroll, R. J. (2001). A note on the efficiency sandwich matrix estimation. *Journal of the American Statistical Association* **96**, 1387–1396.
- Kidwell, K. M. (2014). SMART designs in cancer research: Learning from the past, current limitations and looking toward the future. *Clinical Trials* **11**, 445–456.
- Kidwell, K. M. and Wahed, A. S. (2013). Weighted log-rank statistic to compare shared-path adaptive treatment strategies. *Biostatistics* **14**, 299–312.
- Lavori, P. W. and Dawson, R. (2004). Dynamic treatment regimes: Practical design considerations. *Clinical Trials* **1**, 9–20.
- Li, Z. and Murphy, S. A. (2011). Sample size formulae for two-stage randomized trials with survival outcomes. *Biometrika* **98**, 503–518.
- Li, Z., Valenstein, M., Pfeiffer, P., and Ganoczy, D. (2014). A global logrank test for adaptive treatment strategies based on observational studies. *Statistics in Medicine* **33**, 760–771.
- Lorenzoni, G., Petracci, E., Scarpi, E., Baldi, I., Gregori, D., and Nanni, O. (2023). Use of sequential multiple assignment randomized trials (smarts) in oncology: systematic review of published studies. *British Journal of Cancer* **128**, 1177–1188.
- Lunceford, J. K., Davidian, M., and Tsiatis, A. A. (2002). Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials. *Biometrics* **58**, 48–57.
- Murphy, S. A. (2005). An experimental design for the development of adaptive treatment strategies. *Statistics in Medicine* **24**, 1455–1481.
- Nahum-Shani, I. and Almirall, D. (2019). An introduction to adaptive interventions and SMART designs in education. ncsr 2020-001. *National Center for Special Education Research*.

- Orellana, L., Rotnitzky, A., and Robins, J. M. (2010). Dynamic regime marginal structural mean models for estimation of optimal dynamic treatment regimes, part i: main content. *The International Journal of Biostatistics* **6**, 8.
- Powell, B. L., Moser, B., Stock, W., Gallegher, R. E., Willman, C. L., Stone, R. M., Rowe, J. M., Coutre, S., Feusner, J. H., Gregory, Couban, S., Appelbaum, F. R., Tallman, M. S., and Larson, R. A. (2010). Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. *Blood* **116**, 3751–3757.
- Schaubel, D. E. (2005). Variance estimation for clustered recurrent event data with a small number of clusters. *Statistics in Medicine* **24**, 3037–3051.
- Tsiatis, A. A. (2006). *Semiparametric Theory and Missing Data*. Springer, New York.
- Tsiatis, A. A. and Davidian, M. (2022). Estimating vaccine efficacy over time after a randomized study is unblinded. *Biometrics* **78**, 825–838.
- Tsiatis, A. A., Davidian, M., Holloway, S. T., and Laber, E. B. (2020). *Dynamic Treatment Regimes: Statistical Methods for Precision Medicine*. Chapman and Hall/CRC Press, Boca Raton, FL.
- Wang, X., Turner, E. L., and Li, F. (2023). Improving sandwich variance estimation for marginal cox analysis of cluster randomized trials. *Biometrical Journal* **65**, 2200113.
- Wu, L., Wang, J., and Wahed, A. S. (2023). Interim monitoring in sequential multiple assignment randomized trials. *Biometrics* **79**, 368–380.
- Yang, S., Tsiatis, A. A., and Blazing, M. (2018). Modeling survival distribution as a function of time to treatment discontinuation: A dynamic treatment regime approach. *Biometrics* **74**, 900–909.




Figure 1. Schematic depicting the design of Study C9710. Solid circles represent points of randomization. The four embedded regimes implied by this design are of the form “Give consolidation therapy a initially; if consolidation is completed before the event occurs, give maintenance therapy b ,” where $a = \text{ATRA}$ or $\text{ATRA} + \text{Arsenic Trioxide}$ and $b = \text{ATRA}$ or $\text{ATRA} + \text{MP} + \text{Mtx}$.




Figure 2. Schematic depicting the design of a two-stage SMART with $\mathcal{A}_1 = \{0, 1\}$, $\mathcal{A}_2 = \{2, 3, 4, 5\}$ in which subjects who do not experience the event prior to Decision 2 are classified as responders or nonresponders to Decision 1 treatment and are randomized to stage 2 treatments within feasible subsets of \mathcal{A}_2 depending on their stage 1 treatment and response status; here, $\ell_2 = 4$. Solid circles represent points of randomization. The eight embedded regimes implied by this design are of the form “Give Trt a initially; if the event does not occur before Decision 2 and response, give Trt b , otherwise if the event does not occur before Decision 2 and no response, give Trt c ,” where the eight regimes correspond to $(a, b, c) = (0, 2, 2), (0, 2, 4), (0, 3, 2), (0, 3, 4), (1, 2, 3), (1, 2, 5), (1, 5, 3), (1, 5, 5)$.




Figure 3. Schematic depicting the design of two possible two-stage SMARTs, without and with a control (“standard of care”) regime to which subjects can be randomized up front. In the former design, with no control regime, $\mathcal{A}_1 = \{0, 1\}$; in the latter, $\mathcal{A}_1 = \{0, 1, \text{control}\}$. In either design, subjects who receive stage 1 options Trt 0 or 1 and do not experience the event prior to Decision 2 are classified as nonresponders or responders to Decision 1 treatment, nonresponders continue stage 1 treatment, and responders are randomized to either continue stage 1 treatment or switch; thus, for such subjects $\mathcal{A}_2 = \{0, 1\}$, where 0 indicates continue and 1 indicates switch. Solid circles represent points of randomization. The four embedded regimes excluding the possible control regime are of the form “Give Trt a initially; if the event does not occur before response status is ascertained and nonresponse, continue; else if response, give b ,” where the four regimes correspond to $(a, b) = (0, 0), (0, 1), (1, 0), (1, 1)$.




Figure 4. Estimates of the survival distributions $\mathcal{S}(u, d^j)$ corresponding to embedded Regimes $j = 1, \dots, 4$, shown with dash-dotted, dotted, dashed, and solid lines, respectively. As in the text, the regimes are of the form “Give consolidation therapy a ; if subject completes consolidation before the event occurs, give maintenance therapy b ,” where Regimes 1, 2, 3, 4 take $(a, b) = (0, 0), (0, 1), (1, 0), (1, 1)$, respectively.




Figure 5. Hazards under Scenario 1(a). The solid line is λ_3 , the dashed line is (F.1), and the dotted line is (F.2).




Figure 6. Hazards under Scenario 2(a). The solid line is λ_3 , the dashed line is (F.1), and the dotted line is (F.2).

Table 1

Simulation results under the data generative scenarios described in the text under both the null hypothesis H_0 in (1) and alternatives based on 5000 Monte Carlo (MC) data sets, with all tests conducted with level of significance 0.05. Entries are MC proportions of times the test based on the indicated test statistic rejected H_0 . $\mathbb{Z}_{U,nocov}$ and $\mathbb{Z}_{C,nocov}$ denote the proposed generalized logrank statistics $\mathbb{Z}(\hat{\gamma})$ based on estimated randomization probabilities but without incorporation of covariates using the uncorrected and corrected versions of the covariance matrix $\hat{\Sigma}_{\gamma}$, respectively; $\mathbb{Z}_{U,cov}$ and $\mathbb{Z}_{C,cov}$ denote the same but incorporating all covariates as described in Section D of the Appendix using the uncorrected and corrected versions of the covariance matrix $\hat{\Sigma}_{\gamma}$, respectively; and \mathbb{Z}_{KW} denotes the test statistic proposed by Kidwell and Wahed (2013). Entries under H_0 have MC standard error of approximately 0.003; those under alternatives have MC standard error of about 0.006. In Scenarios 3-5, ζ dictates the alternative; see the text.

Scenario	n	ζ	$\mathbb{Z}_{U,nocov}$	$\mathbb{Z}_{C,nocov}$	$\mathbb{Z}_{U,cov}$	$\mathbb{Z}_{C,cov}$	\mathbb{Z}_{KW}
Null Scenarios							
1(a)	250	–	0.076	0.063	0.074	0.062	0.056
	500	–	0.060	0.053	0.058	0.052	0.053
	1000	–	0.054	0.051	0.054	0.051	0.053
1(b)	250	–	0.071	0.061	0.073	0.059	0.059
	500	–	0.060	0.054	0.057	0.050	0.054
	1000	–	0.056	0.053	0.053	0.050	0.055
2(a)	250	–	0.075	0.060	0.081	0.066	0.081
	500	–	0.060	0.053	0.061	0.053	0.081
	1000	–	0.055	0.051	0.056	0.053	0.081
2(b)	250	–	0.071	0.060	0.074	0.063	0.070
	500	–	0.061	0.054	0.059	0.051	0.072
	1000	–	0.054	0.050	0.054	0.051	0.065
3(a)	250	0.00	0.061	0.051	0.057	0.049	0.052
	500	0.00	0.054	0.049	0.053	0.050	0.049
	1000	0.00	0.051	0.048	0.050	0.048	0.050
3(b)	250	0.00	0.057	0.050	0.060	0.050	0.042
	500	0.00	0.053	0.048	0.052	0.049	0.040
	1000	0.00	0.054	0.050	0.052	0.049	0.044
3(c)	250	0.00	0.063	0.051	0.064	0.053	0.074
	500	0.00	0.056	0.053	0.057	0.051	0.079
	1000	0.00	0.050	0.048	0.057	0.053	0.078
4	375	0.00	0.058	0.050	0.062	0.055	–
	750	0.00	0.055	0.052	0.056	0.052	–
	1500	0.00	0.050	0.049	0.051	0.049	–
5	500	0.00	0.055	0.048	0.055	0.049	–
	1000	0.00	0.056	0.051	0.054	0.050	–
Alternative Scenarios							
1(b)	500	–	0.534	0.487	0.573	0.558	0.468
	1000	–	0.813	0.807	0.891	0.887	0.784
2(b)	500	–	0.455	0.438	0.534	0.515	0.451
	1000	–	0.769	0.761	0.842	0.836	0.766
3(a)	250	3.50	0.726	0.706	0.827	0.807	0.720
	500	2.50	0.719	0.707	0.821	0.812	0.727
	1000	1.75	0.699	0.694	0.808	0.802	0.709
3(b)	250	2.25	0.731	0.711	0.813	0.794	0.709
	500	1.65	0.749	0.736	0.834	0.826	0.730
	1000	1.25	0.817	0.812	0.880	0.875	0.805
3(c)	250	7.00	0.687	0.656	0.808	0.784	0.559
	500	5.25	0.734	0.717	0.857	0.846	0.561
	1000	3.50	0.664	0.656	0.812	0.808	0.466
4	375	2.00	0.713	0.701	0.786	0.774	–
	750	1.50	0.774	0.767	0.852	0.848	–
	1500	1.00	0.728	0.724	0.823	0.818	–
5	500	4.00	0.742	0.729	0.874	0.862	–
	1000	3.00	0.695	0.687	0.847	0.842	–

Table 2

Test statistics and corresponding p -values (in parentheses) for comparisons of embedded regimes as indicated in \mathcal{D} in North American Leukemia Intergroup Study C9710. $\mathbb{Z}_{C,\text{nocov}}$ and $\mathbb{Z}_{C,\text{cov}}$ are the proposed test statistic without and with incorporation of covariates, respectively, and using the bias-corrected covariance matrix; and \mathbb{Z}_{KW} is the appropriate test statistic based on the approach of Kidwell and Wahed (2013). For all test statistics, p -values were obtained from the χ^2 distribution with 3 or 1 degree(s) of freedom as appropriate.

\mathcal{D}	$\mathbb{Z}_{C,\text{nocov}}$	$\mathbb{Z}_{C,\text{cov}}$	\mathbb{Z}_{KW}
$\{d^1, d^2, d^3, d^4\}$	25.990 (< 0.0001)	28.817 (< 0.0001)	23.425 (< 0.0001)
$\{d^3, d^4\}$	3.671 (0.055)	4.241 (0.040)	1.344 (0.246)
$\{d^1, d^2\}$	1.135 (0.287)	2.220 (0.138)	0.832 (0.362)
$\{d^2, d^4\}$	14.638 (0.0001)	14.605 (0.0001)	13.277 (0.0003)
$\{d^1, d^4\}$	20.109 (< 0.0001)	24.717 (< 0.0001)	21.154 (< 0.0001)

Table 3

Simulation results for comparisons of pairs of embedded regimes under data generative scenarios described in Section 3 under both the null hypothesis H_0 in (1) and alternatives based on 5000 Monte Carlo (MC) data sets, with all tests conducted with level of significance 0.05. Entries are as in Table 1 except that \mathbb{Z}_{KW} denotes the test based on the relevant component of the test statistic proposed by Kidwell and Wahed (2013). For each scenario, “3v4” denotes the “shared path” comparison of regimes 3 and 4 (first component of the test of Kidwell and Wahed (2013)) and “xv4” denotes the “non-shared path” comparison of regimes x and 4 (second/third component of the test of Kidwell and Wahed (2013)).

Scenario	n	ζ	$\mathbb{Z}_{U, \text{nocov}}$	$\mathbb{Z}_{C, \text{nocov}}$	$\mathbb{Z}_{U, \text{cov}}$	$\mathbb{Z}_{C, \text{cov}}$	\mathbb{Z}_{KW}
Null Scenarios							
1(a) 3v4	250	–	0.066	0.048	0.064	0.048	0.056
	500	–	0.058	0.047	0.056	0.046	0.050
	1000	–	0.057	0.051	0.057	0.053	0.052
1(a) 2v4	250	–	0.068	0.057	0.067	0.056	0.060
	500	–	0.054	0.047	0.056	0.051	0.051
	1000	–	0.052	0.050	0.052	0.050	0.052
1(a) 1v4	250	–	0.062	0.054	0.065	0.054	0.057
	500	–	0.057	0.051	0.056	0.050	0.056
	1000	–	0.055	0.051	0.053	0.050	0.052
2(a) 3v4	250	–	0.068	0.048	0.068	0.051	0.090
	500	–	0.060	0.051	0.060	0.050	0.085
	1000	–	0.053	0.047	0.051	0.046	0.080
2(a) 2v4	250	–	0.061	0.047	0.067	0.054	0.055
	500	–	0.056	0.048	0.057	0.052	0.053
	1000	–	0.052	0.048	0.053	0.051	0.049
2(a) 1v4	250	–	0.058	0.049	0.062	0.051	0.054
	500	–	0.058	0.050	0.061	0.053	0.053
	1000	–	0.053	0.049	0.057	0.053	0.053
3(a), 3v4	250	0.00	0.063	0.050	0.060	0.049	0.053
	500	0.00	0.050	0.045	0.051	0.045	0.047
	1000	0.00	0.052	0.049	0.056	0.043	0.046
3(a), 2v4	250	0.00	0.058	0.049	0.056	0.044	0.056
	500	0.00	0.055	0.052	0.053	0.049	0.055
	1000	0.00	0.051	0.046	0.054	0.052	0.054
3(a), 1v4	250	0.00	0.056	0.047	0.057	0.049	0.053
	500	0.00	0.053	0.049	0.057	0.051	0.053
	1000	0.00	0.054	0.051	0.051	0.047	0.056
3(c), 3v4	250	0.00	0.059	0.046	0.060	0.046	0.053
	500	0.00	0.054	0.048	0.050	0.045	0.055
	1000	0.00	0.051	0.047	0.056	0.050	0.057
3(c), 2v4	250	0.00	0.055	0.048	0.058	0.049	0.073
	500	0.00	0.050	0.046	0.051	0.045	0.073
	1000	0.00	0.052	0.049	0.051	0.049	0.080
3(c), 1v4	250	0.00	0.057	0.050	0.058	0.050	0.070
	500	0.00	0.055	0.049	0.056	0.051	0.075
	1000	0.00	0.047	0.045	0.048	0.046	0.074
Alternative Scenarios							
3(a), 3v4	1000	1.75	0.195	0.188	0.242	0.234	0.147
3(a), 2v4	1000	1.75	0.581	0.570	0.678	0.671	0.563
3(a), 1v4	1000	1.75	0.845	0.840	0.915	0.911	0.848
3(c), 3v4	1000	3.50	0.625	0.614	0.766	0.755	0.476
3(c), 1v4	1000	3.50	0.340	0.334	0.444	0.435	0.343

Table 4

Simulation results for comparisons of a set of three arbitrary regimes under the null hypothesis H_0 in (1) based on 5000 Monte Carlo (MC) data sets, with all tests conducted with level of significance 0.05. Entries are as in Table 1.

Scenario	n	ζ	$\mathbb{Z}_{U,\text{nocov}}$	$\mathbb{Z}_{C,\text{nocov}}$	$\mathbb{Z}_{U,\text{cov}}$	$\mathbb{Z}_{C,\text{cov}}$
Null Scenario						
3(a)	250	0.00	0.056	0.045	0.062	0.049
	500	0.00	0.054	0.049	0.053	0.048
	1000	0.00	0.051	0.048	0.053	0.050

Table 5

Baseline covariates available from the North American Leukemia Intergroup Study C9710. Race is redefined as indicated in the text.

Variable	Meaning
Age	Age at registration
Gender	1=Male, 2=Female
Race	1=White, 2=Hispanic American, 3=Black/African American, 9=Other
Ethnicity	1=Hispanic, 2=Non-Hispanic, 9=Unknown
WBC	White blood cell count at registration ($10^3/\mu\text{L}$)
Platelet	Platelet count at registration ($10^3/\mu\text{L}$)
ECOG Performance Status	0 = fully active, 1= restricted in strenuous activity, 2 = restricted in work activity, 3 = capable of limited self care, 4 = completely disabled
Risk Group	1=Low (WBC ≤ 10 and Platelet > 40), 2=Intermediate (WBC ≤ 10 and Platelet ≤ 40), 3=High (WBC > 10)
Creatinine	Serum creatinine (mg/dL)
Hemoglobin	Hemoglobin (g/dL)

Table 6

medDRA codes and definitions of the adverse events experienced by at least 5% of patients in North American Leukemia Intergroup Study C9710.

medDRA	Adverse Event Category	Adverse Event
10002646	Gastrointestinal	Anorexia
10012457	Dermatology/skin	Rash/desquamation
10012745	Gastrointestinal	Diarrhea
10013442	Coagulation	Disseminated intravascular coagulation
10013972	Pulmonary	Dyspnea (shortness of breath)
10016288	Infection	Febrile neutropenia, fever of unknown origin without clinically or microbiologically documented infection (ANC $<1.0 \times 10^9/L$, fever ≥ 8.5 degrees C)
10018876	Blood/bone marrow	Hemoglobin
10019218	Pain	Headache
10020637	Metabolic/laboratory	Glucose serum-high (hyperglycemia)
10020947	Metabolic/laboratory	Calcium serum-low (hypocalcemia)
10021015	Metabolic/laboratory	Potassium serum-low (hypokalemia)
10021143	Pulmonary/upper respiratory	Hypoxia
10021842	Infection/febrile neutropenia	Infection without neutropenia
10024285	Blood/bone marrow	Leukocytes (total WBC)
10025327	Blood/bone marrow	Lymphopenia
10028813	Gastrointestinal	Nausea
10029363	Blood/bone marrow	Neutrophils/granulocytes (ANC/AGC)
10033359	Blood/bone marrow	Transfusion: packed red blood cells
10035528	Blood/bone marrow	Platelets
10035543	Blood/bone marrow	Transfusion: platelets
10043607	Vascular	Thrombosis/thrombus/embolism
90004060	Hemorrhage	Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia
90004070	Infection/febrile neutropenia	Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia (ANC $<1.0 \times 10^9/L$)